Interventions to reduce haemorrhage duringmyomectomy for fibroids (Review) by Wiysonge, Charles S. & Kongnyuy, E. J.
Cochrane Database of Systematic Reviews
Interventions to reduce haemorrhage duringmyomectomy for
fibroids (Review)
Kongnyuy EJ, Wiysonge CS
Kongnyuy EJ, Wiysonge CS.
Interventions to reduce haemorrhage during myomectomy for fibroids.
Cochrane Database of Systematic Reviews 2014, Issue 8. Art. No.: CD005355.
DOI: 10.1002/14651858.CD005355.pub5.
www.cochranelibrary.com
Interventions to reduce haemorrhage during myomectomy for fibroids (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
21ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
34DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
40CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
66DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Misoprostol versus placebo, Outcome 1 Blood loss (ml). . . . . . . . . . . . 72
Analysis 1.2. Comparison 1 Misoprostol versus placebo, Outcome 2 Need for blood transfusion. . . . . . . . 73
Analysis 1.3. Comparison 1 Misoprostol versus placebo, Outcome 3 Duration of surgery (min). . . . . . . . 74
Analysis 1.4. Comparison 1 Misoprostol versus placebo, Outcome 4 Postoperative haemoglobin (g/dl). . . . . . 75
Analysis 1.5. Comparison 1 Misoprostol versus placebo, Outcome 5 Duration of hospital stay (days). . . . . . . 75
Analysis 1.6. Comparison 1 Misoprostol versus placebo, Outcome 6 Postoperative haemoglobin drop (g/dl). . . . 76
Analysis 1.7. Comparison 1 Misoprostol versus placebo, Outcome 7 Postoperative complications. . . . . . . . 76
Analysis 2.1. Comparison 2 Vasopressin versus placebo, Outcome 1 Blood loss (ml). . . . . . . . . . . . 77
Analysis 2.2. Comparison 2 Vasopressin versus placebo, Outcome 2 Need for blood transfusion. . . . . . . . 78
Analysis 2.3. Comparison 2 Vasopressin versus placebo, Outcome 3 Duration of surgery (min). . . . . . . . . 79
Analysis 2.4. Comparison 2 Vasopressin versus placebo, Outcome 4 Duration of hospital stay (days). . . . . . . 79
Analysis 2.5. Comparison 2 Vasopressin versus placebo, Outcome 5 Postoperative complications. . . . . . . . 80
Analysis 2.6. Comparison 2 Vasopressin versus placebo, Outcome 6 Pregnancy after myomectomy. . . . . . . 81
Analysis 2.7. Comparison 2 Vasopressin versus placebo, Outcome 7 Conversion of laparoscopy to laparotomy. . . . 81
Analysis 3.1. Comparison 3 Bupivicaine plus epinephrine versus placebo, Outcome 1 Blood loss (ml). . . . . . 82
Analysis 3.2. Comparison 3 Bupivicaine plus epinephrine versus placebo, Outcome 2 Duration of surgery (min). . . 82
Analysis 4.1. Comparison 4 Peri-cervical tourniquet versus no treatment, Outcome 1 Blood loss (ml). . . . . . 83
Analysis 4.2. Comparison 4 Peri-cervical tourniquet versus no treatment, Outcome 2 Need for blood transfusion. . 84
Analysis 4.3. Comparison 4 Peri-cervical tourniquet versus no treatment, Outcome 3 Duration of surgery (min). . . 85
Analysis 4.4. Comparison 4 Peri-cervical tourniquet versus no treatment, Outcome 4 Postoperative complications. . 86
Analysis 5.1. Comparison 5 Oxytocin versus placebo, Outcome 1 Blood loss (ml). . . . . . . . . . . . . 87
Analysis 5.2. Comparison 5 Oxytocin versus placebo, Outcome 2 Need for blood transfusion. . . . . . . . . 88
Analysis 5.3. Comparison 5 Oxytocin versus placebo, Outcome 3 Duration of surgery (min). . . . . . . . . 88
Analysis 5.4. Comparison 5 Oxytocin versus placebo, Outcome 4 Postoperative complications. . . . . . . . . 89
Analysis 5.5. Comparison 5 Oxytocin versus placebo, Outcome 5 Duration of hospital stay (days). . . . . . . . 90
Analysis 6.1. Comparison 6 Chemical dissection with mesna versus placebo, Outcome 1 Duration of surgery (min). . 90
Analysis 6.2. Comparison 6 Chemical dissection with mesna versus placebo, Outcome 2 Duration of hospital stay (days). 91
Analysis 6.3. Comparison 6 Chemical dissection with mesna versus placebo, Outcome 3 Postoperative haemoglobin
(g/dl). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
Analysis 6.4. Comparison 6 Chemical dissection with mesna versus placebo, Outcome 4 Postoperative haematocrit. . 92
Analysis 6.5. Comparison 6 Chemical dissection with mesna versus placebo, Outcome 5 Postoperative complications. 92
Analysis 7.1. Comparison 7 Myoma morcellation versus standard technique of enucleation (no treatment), Outcome 1
Blood loss (ml). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
iInterventions to reduce haemorrhage during myomectomy for fibroids (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.2. Comparison 7 Myoma morcellation versus standard technique of enucleation (no treatment), Outcome 2
Duration of surgery (min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
Analysis 7.3. Comparison 7 Myoma morcellation versus standard technique of enucleation (no treatment), Outcome 3
Duration of hospital stay (days). . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
Analysis 8.1. Comparison 8 Intravenous injection of tranexamic acid versus placebo, Outcome 1 Blood loss (ml). . . 94
Analysis 8.2. Comparison 8 Intravenous injection of tranexamic acid versus placebo, Outcome 2 Need for blood
transfusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
Analysis 8.3. Comparison 8 Intravenous injection of tranexamic acid versus placebo, Outcome 3 Duration of surgery
(min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
Analysis 8.4. Comparison 8 Intravenous injection of tranexamic acid versus placebo, Outcome 4 Postoperative haemoglobin
(g/dl). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
Analysis 8.5. Comparison 8 Intravenous injection of tranexamic acid versus placebo, Outcome 5 Postoperative
haematocrit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
Analysis 9.1. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 1 Blood loss (ml). . 97
Analysis 9.2. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 2 Need for blood
transfusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Analysis 9.3. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 3 Postoperative vaginal
blood loss (ml). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
Analysis 9.4. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 4 Duration of surgery
(min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
Analysis 9.5. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 5 Postoperative
haemoglobin drop (g/dl). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Analysis 9.6. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 6 Duration of hospital stay
(days). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Analysis 9.7. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 7 Postoperative fever. 100
Analysis 10.1. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 1 Blood loss (ml). . . . . 100
Analysis 10.2. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 2 Need for blood transfusion. 101
Analysis 10.3. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 3 Duration of surgery (min). 101
Analysis 10.4. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 4 Duration of hospital stay
(days). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Analysis 10.5. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 5 Posoperative haemoglobin drop
(g/dl). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Analysis 10.6. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 6 Pospoerative hematocrit drop
(%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Analysis 10.7. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 7 Posoperative complications. 103
Analysis 11.1. Comparison 11 Dinoprostone versus placebo, Outcome 1 Blood loss (ml). . . . . . . . . . . 104
Analysis 11.2. Comparison 11 Dinoprostone versus placebo, Outcome 2 Need for blood transfusion. . . . . . . 105
Analysis 11.3. Comparison 11 Dinoprostone versus placebo, Outcome 3 Duration of surgery (min). . . . . . . 105
Analysis 11.4. Comparison 11 Dinoprostone versus placebo, Outcome 4 Duration of hospital stay (days). . . . . 106
Analysis 11.5. Comparison 11 Dinoprostone versus placebo, Outcome 5 Postoperative haemoglobin (g/dl). . . . 106
Analysis 11.6. Comparison 11 Dinoprostone versus placebo, Outcome 6 Postoperative haemoglobin drop (g/dl). . . 107
Analysis 11.7. Comparison 11 Dinoprostone versus placebo, Outcome 7 Postoperative complications. . . . . . 107
Analysis 12.1. Comparison 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment, Outcome 1
Blood loss (ml). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Analysis 12.2. Comparison 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment, Outcome 2
Need for blood transfusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Analysis 12.3. Comparison 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment, Outcome 3
Duration of surgery (min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Analysis 12.4. Comparison 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment, Outcome 4
Duration of hospital stay (days). . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Analysis 13.1. Comparison 13 Temporary clipping of uterine artery versus no treatment, Outcome 1 Need for blood
transfusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
iiInterventions to reduce haemorrhage during myomectomy for fibroids (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 13.2. Comparison 13 Temporary clipping of uterine artery versus no treatment, Outcome 2 Duration of surgery
(min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Analysis 13.3. Comparison 13 Temporary clipping of uterine artery versus no treatment, Outcome 3 Postoperative
haemoglobin drop (g/dl). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Analysis 13.4. Comparison 13 Temporary clipping of uterine artery versus no treatment, Outcome 4 Duration of hospital
stay (days). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
Analysis 13.5. Comparison 13 Temporary clipping of uterine artery versus no treatment, Outcome 5 Postoperative
complications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Analysis 14.1. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 1 Blood loss (ml). . . . . . . 114
Analysis 14.2. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 2 Postoperative blood loss in drainage
bag. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Analysis 14.3. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 3 Need for blood transfusion. . . 115
Analysis 14.4. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 4 Duration of surgery (min). . . 115
Analysis 14.5. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 5 Duration of hospital stay (days). 116
Analysis 14.6. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 6 Conception after surgery. . . . 116
116APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
124FEEDBACK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
125WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
125HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
126CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
126DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
127SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
127DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
127INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiiInterventions to reduce haemorrhage during myomectomy for fibroids (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Interventions to reduce haemorrhage during myomectomy
for fibroids
Eugene J Kongnyuy1 , Charles Shey Wiysonge2 ,3
1Reproductive Health Solutions, Salisbury, UK. 2Centre for Evidence-based Health Care, Stellenbosch University, Cape Town, South
Africa. 3South African Cochrane Centre, South African Medical Research Council, Cape Town, South Africa
Contact address: Eugene J Kongnyuy, Reproductive Health Solutions, 43 Fowler’s Rd, Salisbury, SP1 2QP, UK.
kongnyuy73@yahoo.com.
Editorial group: Cochrane Gynaecology and Fertility Group.
Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 8, 2014.
Review content assessed as up-to-date: 17 June 2014.
Citation: Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database of
Systematic Reviews 2014, Issue 8. Art. No.: CD005355. DOI: 10.1002/14651858.CD005355.pub5.
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Benign smoothmuscle tumours of the uterus, known as fibroids ormyomas, are often symptomless.However, about one-third of women
with fibroids will present with symptoms that are severe enough to warrant treatment. The standard treatment of symptomatic fibroids
is hysterectomy (that is surgical removal of the uterus) for women who have completed childbearing, and myomectomy for women who
desire future childbearing or simply want to preserve their uterus. Myomectomy, the surgical removal of myomas, can be associated
with life-threatening bleeding. Excessive bleeding can necessitate emergency blood transfusion. Knowledge of the effectiveness of the
interventions to reduce bleeding during myomectomy is essential to enable evidence-based clinical decisions. This is an update of the
review published in The Cochrane Library (2011, Issue 11).
Objectives
To assess the effectiveness, safety, tolerability and costs of interventions to reduce blood loss during myomectomy.
Search methods
In June 2014, we conducted electronic searches in the Cochrane Menstrual Disorders and Subfertility Group Specialised Register, the
Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL and PsycINFO, and trial registers for
ongoing and registered trials.
Selection criteria
We selected randomised controlled trials (RCTs) that compared potential interventions to reduce blood loss during myomectomy to
placebo or no treatment.
Data collection and analysis
The two authors independently selected RCTs for inclusion, assessed the risk of bias and extracted data from the included RCTs. The
primary review outcomes were blood loss and need for blood transfusion. We expressed study results as mean differences (MD) for
continuous data and odds ratios for dichotomous data, with 95% confidence intervals (CI). We assessed the quality of evidence using
GRADE methods.
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Main results
Eighteen RCTs with 1250 participants met our inclusion criteria. The studies were conducted in hospital settings in low, middle and
high income countries.
Blood loss
We found significant reductions in blood loss with the following interventions:
vaginal misoprostol (2 RCTs, 89 women: MD -97.88 ml, 95% CI -125.52 to -70.24; I2 = 43%; moderate-quality evidence); in-
tramyometrial vasopressin (3 RCTs, 128 women: MD -245.87 ml, 95% CI -434.58 to -57.16; I2 = 98%; moderate-quality evidence);
intramyometrial bupivacaine plus epinephrine (1 RCT, 60 women: MD -68.60 ml, 95% CI -93.69 to -43.51; low-quality evidence);
intravenous tranexamic acid (1 RCT, 100 women: MD -243 ml, 95% CI -460.02 to -25.98; low-quality evidence); gelatin-thrombin
matrix (1 RCT, 50 women: MD -545.00 ml, 95% CI -593.26 to -496.74; low-quality evidence); intravenous ascorbic acid (1 RCT,
102 women: MD -411.46 ml, 95% CI -502.58 to -320.34; low-quality evidence); vaginal dinoprostone (1 RCT, 108 women: MD -
131.60 ml, 95% CI -253.42 to -9.78; low-quality evidence); loop ligation of the myoma pseudocapsule (1 RCT, 70 women: MD -
305.01 ml, 95% CI -354.83 to -255.19; low-quality evidence); a fibrin sealant patch (1 RCT, 70 women: MD -26.50 ml, 95% CI -
44.47 to -8.53; low-quality evidence), a Foley catheter tied around the cervix (1 RCT, 93 women: MD -240.70 ml, 95% CI -359.61 to
-121.79; low-quality evidence), and a polyglactin suture round both cervix and infundibulopelvic ligament (1 RCT, 28 women: MD -
1870.0 ml, 95% CI -2547.16 to 1192.84; low-quality evidence). There was no good evidence of an effect on blood loss with oxytocin,
morcellation or clipping of the uterine artery.
Need for blood transfusion
We found significant reductions in the need for blood transfusion with vasopressin (2 RCTs, 90 women: OR 0.15, 95% CI 0.03 to
0.74; I2 = 0%; moderate-quality evidence); tourniquet tied round the cervix (1 RCT, 98 women: OR 0.22, 95% CI 0.09 to 0.55; low-
quality evidence); tourniquet tied round both cervix and infundibulopelvic ligament (1 RCT, 28 women: OR 0.02, 95% CI 0.00 to
0.23; low-quality evidence); gelatin-thrombin matrix (1 RCT, 100 women: OR 0.01, 95% CI 0.00 to 0.10; low-quality evidence) and
dinoprostone (1 RCT, 108 women: OR 0.17, 95% CI 0.04 to 0.81; low-quality evidence), but no evidence of effect on the need for
blood transfusion with misoprostol, oxytocin, tranexamic acid, ascorbic acid, loop ligation of the myoma pseudocapsule and a fibrin
sealant patch.
There were insufficient data on the adverse effects and costs of the different interventions.
Authors’ conclusions
At present there is moderate-quality evidence that misoprostol or vasopressin may reduce bleeding duringmyomectomy, and low-quality
evidence that bupivacaine plus epinephrine, tranexamic acid, gelatin-thrombin matrix, ascorbic acid, dinoprostone, loop ligation, a
fibrin sealant patch, a peri-cervical tourniquet or a tourniquet tied round both cervix and infundibulopelvic ligament may reduce
bleeding during myomectomy. There is no evidence that oxytocin, morcellation and temporary clipping of the uterine artery reduce
blood loss. Further well designed studies are required to establish the effectiveness, safety and costs of different interventions for reducing
blood loss during myomectomy.
P L A I N L A N G U A G E S U M M A R Y
Interventions to reduce haemorrhage during myomectomy for treating fibroids
Background
Some women have non-cancerous growths of the uterus, called fibroids. In a third of cases the fibroids produce symptoms, such as
vaginal bleeding, that warrant treatment. The surgical removal of the fibroids, called myomectomy, is one of the treatment options for
fibroids. It can be accomplished by either laparotomy (through an incision into the abdomen) or laparoscopy (keyhole surgery). The
procedure is associated with heavy bleeding. Many interventions have been used by doctors to reduce bleeding during an operation for
removing fibroids but it is unclear whether or not the interventions are effective.
Study characteristics
The evidence is current to June 2014. The review included 18 studies with a total of 1250 women who had myomectomy for uterine
fibroids. All studies compared an intervention to reduce bleeding during myomectomy with either a placebo or no such treatment.
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Key results
The data available suggest that vaginal insertion of misoprostol and infiltration of vasopressin into the uterine muscle are effective
in reducing bleeding during myomectomy. Limited data available also suggest that chemical dissection (such as with mesna), vaginal
insertion of dinoprostone, a gelatin-thrombin matrix, tranexamic acid, infusion of vitamin C (ascorbic acid) during surgery, infiltration
of a mixture of bupivacaine and epinephrine into the uterine muscles, the use of fibrin sealant patch (a surgical patch that improves
blood clotting) or a tourniquet around the cervix or around both the cervix and the infundibulopelvic ligamentmay be effective in
reducing bleeding during myomectomy. We found limited information on the harms (adverse effects) of the different interventions.
Quality of the evidence
There is moderate-quality evidence that misoprostol reduces blood loss by between 70.24 ml and 125.52 ml; with a laparotomy
vasopressin reduces blood loss by between 392.51 and 507.49 ml during myomectomy, and by between 121.73 ml and 172.17 ml
during laparoscopic myomectomy. There is low-quality evidence for the rest of the interventions (chemical dissection, dinoprostone,
gelatin-thrombin matrix, tranexamic acid, vitamin C, mixture of bupivacaine and epinephrine, a fibrin sealant patch and the two types
of tourniquet).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Interventions to reduce blood loss during myomectomy for fibroids compared to placebo or no treatment
Population: Women with fibroids
Settings: Various settings in low income, middle income, and high income countries
Intervention: Diverse interventions
Comparison: Placebo or no treatment
Intervention Illustrative comparative risks (95% CI) on blood
loss
Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Placebo or no treatment Interventions
Misoprostol in abdominal
myomectomy
Mean blood loss with
placebo was
621 ml
Mean blood loss with
misoprostol was
149.00 ml lower
(229.24 to 68.76 lower)
MD -149.00 (-229.24 to
-68.76)
25
(1 study)
⊕⊕⊕©
moderate
We rated down the qual-
ity of evidence (by 1)
because the data were
derived from one small
study
Misoprostol in laparo-
scopic myomectomy
Mean blood loss with
placebo was
322.39 ml
Mean blood loss with
misoprostol was
91.00 ml lower
(120.44 to 61.56 lower)
MD -91.00 (-120.44 to -
61.56)
64
(1 study)
⊕⊕⊕©
moderate
We rated down the qual-
ity of evidence (by 1)
because the data were
derived from one small
study
Vasopressin Mean blood loss with
placebo was
483.09 ml
Mean blood loss with va-
sopressin was
245.87 ml lower
(434.58 to 57.16 lower)
MD -245.87 (-434.58 to
-57.16)
128
(3 studies)
⊕⊕⊕©
moderate
We rated down the qual-
ity of evidence (by 1)
because the data were
derived from three small
studies
Bupivicaine plus
epinephrine
Mean blood loss with
placebo was
212.5 ml
Mean
blood loss with bupivi-
caine-epinephrine was
68.6 ml lower
(93.69 to 43.51 lower)
MD -68.60 (-93.69, -43.
51)
60
(1 study)
⊕⊕©©
low
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, with a high risk of
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attrition bias (2 patients
in each arm did not re-
ceive assigned interven-
tion because of concomi-
tant disease)
Intravenous injection of
tranexamic acid
Mean blood loss with
placebo was
1047 ml
Mean blood loss with
tranexamic was
243 ml lower
(460.02 to 25.98 lower)
MD -243.00 (-460.02 to
-25.980
100
(1 study)
⊕⊕©©
low
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study and the pooled ef-
fect estimate was impre-
cise
Gelatin-thrombin matrix Mean blood loss with
placebo was
625 ml
Mean blood loss with
Gelatin-thrombin was
545 ml lower
(593.26 to 496.74 lower)
MD -545.00 (-593.26 to
-496.74)
50
(1 study)
⊕⊕©©
low
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, and it is unclear if
outcome assessors were
blind
Ascorbic acid Mean blood loss with no
treatment was
932.9 ml
Mean blood loss with
ascorbic acid was
411.46 ml lower
(502.58 to 320.34 lower)
MD -411.46
(-502.58 to -320.34)
102
(1 study)
⊕⊕©©
low
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, and it is unclear
how allocation conceal-
ment was done
Dinopro-
stone (prostaglandin E2
analogue)
Mean blood loss with
placebo was
485.7 ml
Mean blood loss with
dinoprostone was
131.6 ml lower
(253.42 to 9.78 lower)
MD -131.60
(-253.42 to -9.78)
108
(1 study)
⊕⊕©©
low
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, and the effect es-
timate has wide confi-
dence intervals
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Loop ligation of myoma
pseudocapsule plus va-
sopressin
Mean blood loss with no
treatment was
363.68 ml
Mean blood losswith loop
ligation was
305.01 lower
(354.83 to 255.19 lower)
MD -305.01
(-354.83 to -255.19)
70
(1 study)
⊕⊕©©
low
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, and it is unclear
how allocation conceal-
ment was done
Fibrin sealant patch (col-
lagen sponge with throm-
bin and fibrinogen)
Mean blood loss with no
treatment was
151.1 ml
Mean blood loss with
tachosil was
26.5 ml lower
(44.47 to 8.53 lower)
MD -26.50
(-44.47 to -8.53)
70
(1 study)
⊕⊕©©
low
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, and the effect es-
timate has wide confi-
dence intervals
CI: Confidence interval; MD: mean difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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B A C K G R O U N D
Description of the condition
Uterine leiomyomas (fibroids or myomas) are benign, smooth
muscle tumours of the human uterus. Most myomas are asymp-
tomatic (symptomless) and are discovered incidentally during
a routine pelvic examination or imaging studies (Vollenhoven
1990). However, about 20% to 50% of women with myomas
will present with symptoms severe enough to warrant treatment
(Vercellini 1993). Myomas are three times more prevalent in black
women, who tend to have larger, more numerous myomas, than
their white counterparts (Jacoby 2010).
The standard treatment of symptomatic leiomyomas is hysterec-
tomy for women who have completed childbearing, and myomec-
tomy for women who wish to preserve fertility. Hysterectomy,
the surgical removal of the uterus, eliminates both the symptoms
and the chance of recurrence. However, many women who suffer
from myomas desire future childbearing or want to preserve their
uterus. For these womenmyomectomy, the surgical removal of the
myomas with reconstruction and preservation of the uterus, is an
important option. Myomectomy can be accomplished by laparo-
tomy, laparoscopy or hysteroscopy. Myomectomy by laparotomy
involves the surgical removal of the fibroids through an incision
in the abdominal wall. Where there are a small number of sub-
serous or intramural myomas and the uterine size is less than that
of 16 weeks gestation, laparoscopic myomectomy may be an op-
tion (Hurst 2005). The laparoscopic approach is a minimal access
technique (keyhole surgery) developed to minimize insult to the
abdominal wall and to ensure quick recovery of the patient follow-
ing surgery (Hasson 1992). For women with submucous myomas,
transcervical hysteroscopic resection is a good option both for the
gynaecologic surgeons (Derman 1991) and their patients.
Myomectomy can lead to both short and long-term complications.
Complications of hysteroscopic myomectomy include haemor-
rhage, uterine perforation, cervical damage and metabolic distur-
bances from excessive absorption of the distension medium, such
as glycine (Cooper 2000). Laparoscopic myomectomy is associ-
ated with the usual risks of laparoscopy, particularly accidents dur-
ing trocar (a surgical instrument) placement; and, additionally,
excessive uncontrolled haemorrhage with the need to convert to a
laparotomy and the risk of uterine rupture in subsequent pregnan-
cies (Dubuisson 1997). Short-term complications of abdominal
myomectomy include bleeding, fever, infection, visceral damage
and thromboembolism (LaMote 1993). A requirement for trans-
fusion in up to 20% of cases following abdominal myomectomy
has been reported in the literature (LaMote 1993). Patients under-
going myomectomy have an unusually high incidence of fever oc-
curring in the first 48 hours following surgery (Iverson 1999). The
incidence of postoperative fever following myomectomy has been
reported to be as high as 36% (Celik 2003). The cause is unknown
but it is believed that ’myomectomy fever’ is due to the release of
pyrogenic (fever-inducing) factors during myoma dissection or to
haematomas (blood clots) forming in defects left by the removed
myomas. In 2% of cases there is a need for conversion of myomec-
tomy to hysterectomy (Aubuchon 2002). Long-term complica-
tions of abdominal myomectomy include pelvic adhesions in 59%
of women after two years (Frederick 2002) and recurrent fibroids
in 46.0% of women after one year (Nishiyama 2006). The risk of
uterine rupture in subsequent pregnancies varies between 0% and
1% (Garnet 1964; Tulandi 1993; Fedele 1995; Somigliana 2008).
Blood loss during myomectomy can be intraoperative or postop-
erative and with haematoma formation. Massive blood loss asso-
ciated with the dissection of huge fibroids renders myomectomy a
more technically challenging procedure than hysterectomy. Some-
times myomectomy is converted to hysterectomy intraoperatively
when bleeding becomes heavy and uncontrollable or when it is
impossible to reconstruct the uterus because of the many defects
left by the removal of multiple myomas (Iverson 1996). Excessive
bleeding can necessitate emergency blood transfusion.
Description of the intervention
Many interventions have been performed to reduce bleeding dur-
ing myomectomy. Four categories of interventions can be identi-
fied:
• interventions on uterine arteries such as laparoscopic
uterine artery dissection, uterine artery embolization, peri-
cervical mechanical tourniquet, vasopressin (natural or
synthetic), a vasoconstrictive solution of bupivacaine plus
epinephrine, and temporary clipping of the uterine artery;
• utero-tonics such as ergometrine, oxytocin, misoprostol,
and sulprostone;
• myoma dissection techniques which include myoma
enucleation by morcellation and the use of laser and chemical
dissectors such as sodium-2-mercaptoethane sulphonate (mesna);
• pharmacologic manipulation of the coagulation cascade
with antifibrinolytic agents such as tranexamic acid, aprotinin,
aminocaproic acid, recombinant factor VIIa (Koh 2003), and
gelatin-thrombin haemostatic sealant.
In developed countries, gonadotrophin-releasing hormone
(GnRH) analogues (GnRHa) have been used prior to myomec-
tomy. There is now clear evidence that the use of GnRH analogues
reduces uterine volume and fibroid size and may reduce blood
loss and operating time during myomectomy (Lethaby 2001). Al-
though the use of preoperative GnRHa leads to less frequent ver-
tical incisions in the case of myomectomy, a review of the cost-
effectiveness of GnRHa found that the costs outweigh its benefits
(Farquhar 2002). In addition, uterine artery embolization (UAE)
has been used as an alternative to myomectomy (Lumsden 2002)
and to prevent haemorrhage during myomectomy (Ngeh 2004).
However, there are currently no randomised trials comparingUAE
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with a placebo or no treatment with regard to blood loss during
myomectomy. In low and middle income countries, however, the
cost of using GnRH analogues andUAEmay be prohibitive (espe-
cially where there is an out-of-pocket payment) and the necessary
technology may not be available.
How the intervention might work
The mechanical tourniquet has been used during myomectomy
to reduce intraoperative blood loss (Hutchins 1996). However,
the pressure exerted by the tourniquet may cause damage to the
uterine artery and its branches, and mask inadequate haemosta-
sis (arrest of bleeding), which only becomes apparent once the
tourniquet is removed. Uterine artery ligation can reduce both
intraoperative and postoperative haemorrhage (Sapmaz 2003B).
Hormonal tourniquets such as natural or synthetic vasopressin act
on vasopressin V1a receptors, ubiquitously expressed in the my-
ometrium, to reduce blood loss (Fletcher 1996; Dimitrov 1999;
Kimura 2002). Hormonal tourniquets act as peri-cervical tourni-
quets when administered in the cervix but act as utero-tonics when
administered in the myometrium. Preoperative UEA is a tech-
nique for the treatment of myomas which reduces uterine size and
controls symptoms (Ravina 1995). It may also be a useful adjunct
to surgery in women with massive fibroids (Ngeh 2004). Laparo-
scopic dissection of uterine vessels (LDUV) using ultrasonically
activated shears for the treatment of fibroids has been reported
to reduce uterine volume and symptoms (Holub 2003). Laparo-
scopic bipolar coagulation of the uterine blood vessels has recently
been described as an alternative to UAE but a high degree of la-
paroscopic skill is required to isolate the uterine artery without
causing damage to the ureters or blood vessels (Liu 2001).
Utero-tonics such as ergometrine, oxytocin, misoprostol and sul-
prostone cause myometrial contraction and, therefore, potentially
reduce blood loss during myomectomy leading to better anatomi-
cal reconstruction of the uterus (Baldoni 1995). Ergometrine may
raise blood pressure while misoprostol may cause fever after its
administration.
Myoma dissection techniques include the use of carbon dioxide
laser and mesna for chemical dissection (McLaughin 1985). These
procedures have the potential to minimize uterine defects from fi-
broid removal thereby facilitatinguterine reconstruction, although
they may be time consuming.
The coagulation cascade can be modified with the use of pharma-
cologic agents such as tranexamic acid, aprotinin, aminocaproic
acid, recombinant factor VIIa and gelatin-thrombin haemostatic
sealant. These agents interfere with one or more stages of the co-
agulation cascade, from activation of coagulation to stabilisation
of the fibrin clot. The end result is the formation of a stable clot
that stops or prevents bleeding.
Why it is important to do this review
Excessive haemorrhage duringmyomectomy remains amajor chal-
lenge to gynaecologic surgeons despite the many procedures that
have been described to reduce intraoperative blood loss. The ef-
fects of these procedures on blood loss during myomectomy, as
reported by previous non-randomised studies, have been inconsis-
tent. Moreover, the types of interventions are so varied that there
is a need to identify the most effective procedures with minimal
adverse effects to help the gynaecologic surgeon to make a correct
choice.
The aim of this review was to establish which are the most ef-
fective interventions with the fewest adverse effects. The use of
preoperative GnRHa was not considered in this review because
their effectiveness has been examined in a separate Cochrane re-
view (Lethaby 2001).
O B J E C T I V E S
To assess the effectiveness, safety, tolerability and costs of inter-
ventions to reduce blood loss during myomectomy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published and unpublished randomised controlled trials (RCTs)
were eligible for inclusion. We excluded non-randomised studies
(for example studies with evidence of inadequate sequence gen-
eration, such as patient numbers and alternate days) as they are
associated with a high risk of bias.
Types of participants
Premenopausal womenundergoingmyomectomy (laparotomy, la-
paroscopy or hysteroscopy) for uterine fibroids, for any reason,
were eligible for inclusion. Women who had previously had a my-
omectomy were also included.
Types of interventions
Trials comparing any intervention used to reduce blood loss dur-
ing myomectomy versus either placebo or no treatment were eli-
gible for inclusion. Only interventions performed during surgery,
immediately before surgery, or within the 24 hour period prior
to surgery were considered for this review. Interventions that in-
volved GnRHa were excluded because their effectiveness has been
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examined in a separate Cochrane review (Lethaby 2001). The in-
terventions, compared to placebo or no treatment, that were con-
sidered in this review were:
• utero-tonics (such as ergometrine, oxytocin, misoprostol,
and sulprostone);
• vasopressin (natural or synthetic);
• uterine artery dissection and ligation;
• peri-cervical mechanical tourniquet;
• uterine artery embolization (UAE);
• laser dissection;
• myoma enucleation by morcellation;
• chemical dissection (such as sodium-2-mercaptoethane
sulphonate (mesna));
• antifibrinolytic agents (such as tranexamic acid);
• temporary clipping of the uterine artery;
• use of a gelatin-thrombin haemostatic sealant.
Types of outcome measures
Trials with at least one of the following outcomes were eligible for
inclusion.
Primary outcomes
• Estimated blood loss in millilitres (ml)
• Need for blood transfusion (as defined by trial authors)
Secondary outcomes
1. Effectiveness outcomes:
a) postoperative haemoglobin and haematocrit;
b) postoperative recurrence of myomas;
c) pregnancy (if pregnancy desired).
2. Safety outcomes:
a) duration of operation;
b) intraoperative hysterectomy;
c) conversion from laparoscopy to laparotomy;
d) other intraoperative complications (e.g. perforation, cervical
damage);
e) duration of hospital stay in days;
f ) postoperative morbidity (i.e. complications such as pyrexia, in-
fection, thromboembolism, haematoma formation, and postop-
erative adhesions) as defined by the trial authors;
g) abdominal revisions for haemoperitoneum or pelvic
haematoma;
h) treatment adherence (i.e. the proportion of patients who con-
tinued with the allocated treatment);
i) tolerability to the intervention, as defined by trial authors.
3. Cost outcomes:
a) cost of intervention;
b) total cost.
Search methods for identification of studies
We searched for all published and unpublished RCTs of my-
omectomy, without language restrictions and in consultation with
the Menstrual Disorders and Subfertility Group (MDSG) Trials
Search Co-ordinator.
Electronic searches
The original searches were performed in March 2006 and subse-
quent searches were in September 2008, February 2011, October
2013 and 17 June 2014. In June 2014, we searched the following
databases, trial registers and websites.
(1) The Cochrane Menstrual Disorders and Subfertility Group
Specialised Register, Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, CINAHL and
PsycINFO.
(2) Other electronic sources of trials included the following.
• Trial registers for ongoing and registered trials:
◦ http://www.clinicaltrials.gov (a service of the US
National Institutes of Health);
◦ http://www.who.int/trialssearch/Default.aspx (World
Health Organization International Clinical Trials Registry
Platform search portal).
• PubMed (for recent trials not yet indexed in MEDLINE).
• DARE (Database of Abstracts of Reviews of Effects) in The
Cochrane Library at http://onlinelibrary.wiley.com/o/cochrane/
cochrane_cldare_articles_fs.html (for reference lists from
relevant non-Cochrane reviews).
Searching other resources
We handsearched reference lists of identified trials and relevant re-
view articles, specialist journals, conference abstracts. In addition,
we contacted experts in the field to obtain additional data.
Data collection and analysis
Selection of studies
The Trials Search Co-ordinator of the Cochrane Menstrual Disor-
ders and Subfertility Group and the lead author (EJK) conducted
the literature search. After an initial screen of the titles and ab-
stracts retrieved by the search, conducted by EJK, the full texts of
all potentially eligible studies were retrieved. Both authors (EJK
andCSW) independently examined these full text articles for com-
pliance with the inclusion criteria and selected studies eligible for
inclusion in the review. We also contacted the study investigators,
as required, to clarify study eligibility. Any disagreements as to the
study eligibility were resolved by discussion and consensus. The
selection process was documented in a PRISMA flow chart.
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Data extraction and management
The two authors (one a topic area specialist and one a method-
ologist) independently extracted the data from the eligible trials
using a data extraction form designed and pilot-tested by the au-
thors. We then compared the results and any disagreements were
resolved by discussion. The following information was extracted
from each of the included studies.
Characteristics of trials:
• power calculation;
• method of randomisation;
• blinding of patients, caregivers, outcome assessors, and
investigators to treatment allocation;
• quality of allocation concealment;
• number of patients randomised, excluded, and lost to
follow up;
• handling in the analysis of losses to follow up and lack of
compliance with the intervention;
• duration, timing, and location of the study.
Characteristics of the study participants:
• age, ethnic background, and any recorded characteristics of
the study participants such as size of fibroids and reason for
myomectomy;
• other inclusion criteria;
• exclusion criteria.
Interventions:
• types of interventions;
• dose, timing, duration, and route of administration of the
treatment;
• technique of myomectomy (abdominal, laparoscopic, or
hysteroscopic).
Outcomes:
• types of outcomes measured or reported;
• methods used to assess outcome measures.
Where studies had multiple publications, the main trial report
was used as the reference and additional details were derived from
secondary articles.We contacted the study investigators for further
data on methods and results, as required.
Assessment of risk of bias in included studies
The two authors independently assessed the risk of bias in
the included trials by addressing the seven specific domains of
the Cochrane risk of bias assessment tool (www.cochrane-hand-
book.org): selection (random sequence generation and allocation
concealment); performance (blinding of participants and person-
nel); detection (blinding of outcome assessors); attrition (incom-
plete outcome data); reporting (selective outcome reporting); and
other bias, as outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). For risk of bias assessment
we were not blinded to the names of the trial investigators, their
institutions, journals of publication, nor results of the study. For
each included trial we described all judgments fully and presented
the conclusions in the risk of bias tables. The risk of bias was incor-
porated into the interpretation of the review findings by means of
a sensitivity analysis. We searched for within-trial selective report-
ing, such as trials failing to report obvious outcomes or reporting
them in insufficient detail to allow for inclusion.
Measures of treatment effect
We performed statistical analysis using RevMan 5.2. For dichoto-
mous data, we used numbers of events in the control and interven-
tion groups of each study to calculate the Mantel-Haenzel odds
ratios (OR) with 95% confidence intervals (CI). For continuous
data, if all studies reported exactly the same outcomes we calcu-
lated the mean difference (MD) between the groups. If they re-
ported similar outcomes, we recorded the means and their stan-
dard deviations for each arm of the trial and expressed study results
as mean difference (MD) with a 95% CI. We would have used
standardised mean difference (SMD) if similar outcomes were re-
ported on different scales across studies. If data to calculate the
ORs and MDs were not available, we would have used the most
detailed numerical data available that might have facilitated sim-
ilar analyses of included studies (for example P values). We com-
pared the magnitude and direction of effect reported by the stud-
ies with how they were presented in the review, taking account of
legitimate differences.
Unit of analysis issues
The primary analysis was performed per woman randomised. We
planned to check for ’unit-of-analysis error’ in cluster-randomised
controlled trials. Unit-of-analysis error occurs if individuals in a
cluster-randomised trial are assumed to be independent and clus-
tering is ignored during the analysis. We planned to handle these
issues according to the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
Dealing with missing data
Data were analysed on an intention-to-treat basis as far as possible.
Where data were missing we contacted the study investigators and
requested the missing data. Where only the median was reported
we assumed that the mean was equal to the median and imputed
the standard deviation from trials with similar values and sample
sizes. Where similar trials were not available, we discussed the re-
sults of the study in a narrative format. If studies reported suffi-
cient detail to calculate the mean differences but had no informa-
tion on the associated standard deviation (SD), the outcome was
assumed to have a SD equal to the highest SD from other studies
within the same analysis.
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Assessment of heterogeneity
We considered whether the clinical andmethodological character-
istics of the included trials were sufficiently similar for meta-analy-
sis to provide a clinically meaningful summary. We assessed statis-
tical heterogeneity by the I2 statistic. An I2 value greater than 50%
was taken to indicate substantial heterogeneity (Higgins 2011).
Assessment of reporting biases
We planned to assess publication bias by looking for funnel plot
asymmetry if there were 10 or more studies in an analysis. In view
of the difficulty of detecting and correcting for publication bias
and other reporting biases, attempts were made to reduce report-
ing bias by searching multiple sources of electronic databases and
additional sources for both published and unpublished articles.
Data synthesis
If the studies were sufficiently similar, we carried out a meta-anal-
ysis of results from trials using the fixed-effect model (DeMets
1987). However, when significant heterogeneity was found we
reported the results of the random-effects model (DerSimonian
1986) and explored potential sources of heterogeneity. We anal-
ysed trial participants in the groups to which they were ran-
domised, regardless of whether they actually received the assigned
treatment.
Higher values of postoperative haemoglobin and haematocrit,
pregnancy after myomectomy, and treatment adherence were con-
sidered a benefit rather than adverse consequences of treatment, so
the presence of the effect estimates (MD,OR) and CIs to the right
side of the forest plots (rather than to the left as with blood loss and
other outcomes) was considered to show a benefit of treatment.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analyses based on the technique
of myomectomy (laparotomy, laparoscopy, or hysteroscopy), and
type of comparison group (placebo or no treatment).
Sensitivity analysis
We planned to perform a sensitivity analysis by considering
whether the review conclusions would have differed if:
1. studies with high risk of bias had been excluded;
2. a random-effects model had been adopted;
3. the summary effect measure was risk ratio rather than odds
ratio (OR);
4. we excluded studies with imputed data.
Overall quality of the body of evidence: summary of findings
table
We generated summary of findings tables using the GRADEPRO
software. These tables present the overall quality of the body of
evidence for main review outcomes (that is blood loss, need for
blood transfusion, and duration of surgery) taking into consid-
eration study limitations (that is risk of bias), consistency of ef-
fect, imprecision, indirectness, and publication bias. Judgments
about evidence quality (high, moderate or low) was justified, doc-
umented, and incorporated into reporting of results for each out-
come (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; Summary of findings 6; Summary of
findings 7).
R E S U L T S
Description of studies
Results of the search
The search retrieved 623 records. Forty-one studies were poten-
tially eligible and were retrieved in full text. Eighteen studies met
our inclusion criteria. Twenty-three studies were excluded and two
are ongoing.
The October 2013 search identified six additional trials (
Kalogiannidis 2011; Leone Maggiore 2011; Zhao 2011;
Pourmatroud 2012; Vercellino 2012; Shokeir 2013) to the 12
trials that were included in the previous version of the review
(Kongnyuy 2011). See study tables: Characteristics of included
studies; Characteristics of excluded studies; and Characteristics of
ongoing studies. The search and selection processes for the review
are shown in Figure 1.
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Figure 1. Flow diagram showing screening of search outputs and study selection.
Included studies
Study design and setting
Eighteen parallel-design randomised controlled trials (RCTs) were
included in the review. The studies were conducted in hospital
settings in low, middle and high income countries. All studies
were carried out in one centre except for two studies (Taylor 2005;
Vercellino 2012) that were conducted in two or more centres.
Participants
The studies included 633 women in the intervention groups and
617 in the control groups. All were women of reproductive age
with uterine myomas and wished to preserve their uteri. Most
women had symptomatic fibroids. One trial included only infer-
tile women (Assaf 1999). There were no significant differences
between the treatment and control groups at baseline in all trials
but one (Taylor 2005), in which there was a significant difference
in the mean age: 39.5 years in the control group and 42.6 years in
the treatment group.
Interventions
• 3/18 studies compared vasopressin versus placebo
• 1/18 studies compared bupivacaine combined with
epinephrine versus placebo
• 1/18 studies compared peri-cervical tourniquet versus no
treatment
• 1/18 studies compared a tourniquet round both cervix and
infundibulopelvic ligament versus no treatment
• 2/18 studies compared oxytocin versus placebo
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• 2/18 studies compared misoprostol versus placebo
• 1/18 studies compared chemical dissection with mesna
versus placebo
• 1/18 studies compared morcellation while attached to the
uterus versus no treatment
• 1/18 studies compared gelatin-thrombin matrix versus
placebo
• 1/18 studies compared ascorbic acid versus no treatment
• 1/18 studies compared dinoprostone versus placebo
• 1/18 studies compared loop ligation of myoma
pseudocapsule combined with vasopressin versus no treatment
• 1/18 studies compared temporary clipping of uterine artery
versus no treatment
• 1/18 studies compared fibrin sealant patch (surgical collagen
patch coated with thrombin and fibrinogen) versus no treatment
Eight of the trials included in this review used laparoscopic my-
omectomy (Assaf 1999; Zullo 2004; Sinha 2005; Wang 2007;
Kalogiannidis 2011; LeoneMaggiore 2011;Zhao2011;Vercellino
2012), one trial included cases that had myomectomy by either
the vaginal route or laparotomy (Agostini 2005) and the rest of
the trials used myomectomy by laparotomy only.
Outcomes
• 16/18 studies reported blood loss (ml) during myomectomy
• 13/18 studies reported need for blood transfusion
• 16/18 studies reported duration of surgery
• 11/18 studies reported duration of hospital stay (days)
• 5/18 studies reported postoperative haemoglobin
• 5/18 studies reported postoperative haemoglobin drop
• 8/18 reported postoperative morbidity
• 1/18 reported pregnancy rate following surgery
• 0/18 reported cost of intervention
Excluded studies
Twenty-three studies were excluded from the review, for the fol-
lowing reasons:
• 10/23 were not RCTs;
• 13/23 had ineligible control groups.
Risk of bias in included studies
We have summarised our risk of bias assessments in Figure 2 and
Figure 3.
Figure 2.
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Figure 3.
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Allocation
Ten studies were at low risk of selection bias related to sequence
generation as they used computer randomisation or a random
numbers table. The other eight studies did not describe themethod
used and were at unclear risk of this bias. Ten studies were at
low risk of selection bias related to allocation concealment as they
used adequate allocation concealment methods such as sequen-
tially numbered opaque sealed envelopes. The other eight studies
did not describe the method used and were at unclear risk of this
bias.
Blinding
Blinding of participants and personnel
We did not consider that blinding was likely to influence find-
ings for the primary review outcome (blood loss and need for
blood transfusion). However, for secondary outcomes such as op-
erative difficulties, postoperative morbidity including subjective
outcomes such as severe pain, as well as tolerability and safety,
blinding status could potentially affect the findings. Twelve studies
described the use of a double-dummy placebo that was identical
to the intervention and were thus deemed to be at low risk of per-
formance bias. The other six studies were considered to be at high
risk of performance bias because either the care givers and patients
were not blinded or because there were no placebo control groups.
Blinding of outcome assessors
Nine studies described blinding of outcome assessors and we
judged them to be at low risk of detection bias. Two studies were
judged to be at high risk of detection bias because the outcome as-
sessors were not blinded. The other seven studies did not describe
the blinding of assessors and were at unclear risk of this bias.
Incomplete outcome data
Sixteen studies analysed all or most (> 95%) of the women that
were randomised and we judged them to be at low risk of bias.
Two studies were considered to be at high risk of attrition bias: in
both studies some participants (6.7% in one study and 8.3% in
the other) were excluded after randomisation.
Selective reporting
We did not have access to the study protocols and therefore could
not judge whether the studies reported all planned outcomes. The
trial on mesna versus placebo did not report blood loss. The trials
on bupivacaine plus epinephrine, chemical dissection with mesna,
myomamorcellation, temporary clipping of the uterine artery and
fibrin sealant patch did not report the need for blood transfusion.
Trials on bupivacaine plus epinephrine, mesna, myoma morcella-
tion, temporary clipping of uterine artery and fibrin sealant patch
did not report on the adverse effects.
Other potential sources of bias
In one study (Taylor 2005) there was a substantial baseline dif-
ference in age between the two groups and the risk of bias was
deemed high. We found no potential sources of within-study bias
in the other 17 studies.
Effects of interventions
See: Summary of findings for the main comparison
Interventions to reduce blood loss during myomectomy for
fibroids compared to placebo or no treatment; Summary of
findings 2 Misoprostol compared to placebo to reduce blood
loss during myomectomy for fibroids; Summary of findings
3 Vasopressin versus placebo to reduce blood loss during
myomectomy for fibroids; Summary of findings 4 Bupivicaine
plus epinephrine compared to placebo to reduce blood loss
during myomectomy for fibroids; Summary of findings 5 Peri-
cervical tourniquet compared to no treatment to reduce blood
loss during myomectomy for fibroids; Summary of findings 6
Gelatin-thrombin matrix compared to placebo or no treatment
to reduce blood loss during myomectomy for fibroids; Summary
of findings 7 Ascorbic acid compared to no treatment to reduce
blood loss during myomectomy for fibroids
Summary of findings for the main comparison presents the effects
of different interventions on blood loss during myomectomy.
1. Comparision of misoprostol versus placebo
Primary outcomes
1.1. Blood loss
Misoprostol was associated with significant reduction in blood
loss compared to placebo (2 RCTs, 89 women: MD -97.88 ml,
95% CI -125.52 to -70.24; I2 = 43%; moderate-quality evidence;
Analysis 1.1; Summary of findings 2).
A subgroup analysis showed a significant reduction in blood loss
in both the abdominal myomectomy group (1 RCT, 25 women:
MD -149.00 ml, 95%CI -229.24 to - 68.76) and the laparoscopic
myomectomy group (1 RCT, 64 women: MD -91.00 ml, 95% CI
-120.44 to -61.56).
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1.2. Need for blood transfusion
One trial involving 25 women found no evidence of effect of
misoprostol on the need for blood transfusion (OR 0.36, 95% CI
0.05 to 2.50), and no woman needed a blood transfusion in the
second trial involving 64 women (Analysis 1.2). We judged the
quality of the evidence on the effect of misoprostol on the need
for blood transfusion as low (Summary of findings 2).
Secondary outcomes
1.3. Postoperative haemoglobin
Misoprostol was associated with higher postoperative haemoglo-
bin compared to placebo (2 RCTs, 89 women: MD 0.69 g/dl, 95
CI 0.37 to 1.02; I2 = 0%; Analysis 1.4).
1.4. Duration of surgery
There was no evidence that the use of misoprostol changed the
duration of surgery (Summary of findings 2). The results were
not pooled as pooling led to substantial heterogeneity (I2 = 88%),
which could be explained by the fact that in one study myomec-
tomy was achieved by laparotomy and in the other study myomec-
tomy was performed by laparoscopy.
A subgroup analysis showed a significant reduction of blood loss in
the abdominalmyomectomy group (1RCT, 25women:OR -9.50,
95%CI -15.90 to -3.10) but not in the laparoscopic myomectomy
group (1 RCT, 64 women: OR 9.00 min, -1.63 to 19.63).
1.5. Duration of hospital stay
There was no evidence of effect on the duration of hospital stay (1
RCT, 25 women: MD 0.00 days, 95% CI -0.82 to 0.82; Analysis
1.5).
1.6. Postoperative morbidity
There was no evidence of effect on febrile morbidity compared to
placebo (2 RCTs, 89 women: OR 0.94, 95% CI 0.23 to 3.88; I2
= 0%; Analysis 1.7).
2. Vasopressin versus placebo
Primary outcomes
2.1. Blood loss
There was significant heterogeneity between the studies that as-
sessed the effect of vasopressin. The heterogeneity between stud-
ies could be explained by the fact that in one study women had
laparoscopic myomectomy and in two other studies the women
had open abdominal myomectomy.
A subgroup analysis revealed that when compared to placebo, va-
sopressin was associated with significant reduction in blood loss
during abdominal myomectomy (1 RCT, 20 women: MD -450
ml, 95% CI -507.49 to -392.51) as well as during laparoscopic
myomectomy (2 RCTs, 108 women: MD -147.95 ml, 95% CI -
174.17 to -121.73; I2 = 0%; Analysis 2.1).
2.2. Need for blood transfusion
Vasopressin was associated with a reduction in the need for blood
transfusion compared to placebo (2 RCTs, 90 women: OR 0.15,
95%CI0.03 to 0.74; I2 =0%;moderate-quality evidence; Analysis
2.2) (Summary of findings 3).
A subgroup analysis showed no significant reduction in the need
for blood transfusion in both the abdominal myomectomy group
(1 RCT, 20 women: OR 0.11, 95% CI 0.01 to 1.24) and laparo-
scopic myomectomy group (1 RCT, 70 women: OR 0.18, 95%
CI 0.02 to 1.60).
Secondary outcomes
2.3. Pregnancy (if desired)
There was no evidence of a difference in pregnancy one year af-
ter myomectomy between vasopressin and placebo (1 RCT, 38
women: OR 0.64, 95% CI 0.18 to 2.31; Analysis 2.6).
2.4. Duration of surgery
Vasopressin was associated with a reduction in the operating time
compared to placebo (2 RCTs, 108 women:MD -27.72 min, 95%
CI -35.82 to -19.61; I2 = 0%; moderate-quality evidence; Analysis
2.3) (Summary of findings 3).
2.5. Length of hospital stay
There was no evidence of a difference in the length of hospital stay
between vasopressin and placebo (2 RCTs, 108 women: MD 0.11
days, 95% CI -0.69 to 0.91; P = 0.96; I2 = 75%; Analysis 2.4).
2.6. Conversion of laparoscopy to laparotomy
Compared to placebo, there was no evidence of an effect of vaso-
pressin on conversion of laparoscopy to laparotomy (1 RCT, 70
women: OR 7.65, 95% CI 0.38 to 153.75; Analysis 2.7).
2.7. Postoperative adhesions
Compared to placebo, there was no evidence of an effect of vaso-
pressin on postoperative adhesions (1 RCT, 38 women: OR 2.02,
95% CI 0.54 to 7.49; Analysis 2.5).
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3. Bupivacaine plus epinephrine versus placebo
Primary outcomes
3.1. Blood loss
Compared to placebo, bupivacaine plus epinephrine significantly
reduced blood loss (1 RCT, 60 women: MD -68.6 ml, 95% CI -
93.69 to -43.51; low-quality evidence; Analysis 3.1) (Summary of
findings 4).
3.2. Need for blood transfusion
The need for blood transfusion was not reported by investigators.
Secondary outcomes
3.3. Duration of surgery
Bupivicaine plus epinephrine was associated with a reduction in
the operating time compared to placebo (1 RCT, 60 women: MD
-30.50 min, 95% CI -37.68 to -23.32; low-quality evidence;
Analysis 3.2) (Summary of findings 4).
3.4. Other secondary outcomes
Other secondary outcomes were not reported by investigators.
4. Peri-cervical tourniquet versus no treatment
Primary outcomes
4.1. Blood loss
There was significant heterogeneity between studies that evalu-
ated the effect of a peri-cervical tourniquet (I2 = 95%; Analysis
4.1). Due to the significant heterogeneity between the studies,
the studies were not combined. We attributed the heterogene-
ity between studies to the different methods used for the peri-
cervical tourniquet. One study (Taylor 2005) used a polyglactin
suture tied around the cervix to occlude the uterine artery and
left there after surgery, plus a polythene tourniquet tied round
the infundibulopelvic ligament and removed after the operation.
This study found a significant effect in blood loss, favouring the
use of the tourniquet (1 RCT, 28 women: MD -1870.0, 95% CI
-2547.16 to -1192.84; low-quality evidence ). The other study
(Ikechebelu 2010) used a Foley catheter that was tied round the
base of the uterus and was released intermittently during surgery;
and also revealed evidence that a peri-cervical tourniquet reduced
blood loss compared to no treatment (1 RCT, 93 women: MD -
240.70, 95% CI -359.61 to -121.79; low-quality evidence).
4.2. Need for blood transfusion
Peri-cervical tourniquet was associated with a significantly re-
duced need for blood transfusion compared to placebo (1 RCT,
98 women: OR 0.22, 95%CI 0.09 to 0.55; low-quality evidence).
The use of a tourniquet around both the cervix and the infundibu-
lopelvic ligament also significantly reduced blood loss (1 RCT, 28
women: OR 0.02, 95% CI 0.00 to 0.23; low-quality evidence).
Secondary outcomes
4.3. Duration of surgery
There was no evidence of an effect on operating time with a peri-
cervical tourniquet compared to no treatment (1 RCT, 28 women:
MD -4.00 min, 95% CI -29.28 to 21.28; low quality evidence;
Analysis 4.3) (Summary of findings 5).
4.4. Postoperative morbidity
Peri-cervical tourniquet had no evidence of an effect on postop-
erative morbidity (Analysis 4.4): fever (1 RCT, 93 women: OR
1.09, 95% CI 0.46 to 2.59; Analysis 4.4), anaemia (1RCT, 93
women: OR 1.09, 95% CI 0.46 to 2.59), urinary tract infection
(1 RCT, 93 women: OR 0.71, 95% CI 0.13 to 3.70), prolonged
vaginal bleeding (1 RCT, 93 women: OR 2.21, 95% CI 0.09 to
55.82), pelvic abscess (1 RCT, 93 women: OR 2.21, 95% CI 0.09
to 55.82), and intestinal obstructions (1 RCT, 93 women: OR
2.21, 95% CI 0.09 to 55.82).
5. Oxytocin versus placebo
Primary outcomes
5.1. Blood loss
The effect of oxytocin on blood loss compared to placebo was
inconsistent with significant heterogeneity across studies. There
was no obvious explanation for the heterogeneity. A subgroup
analysis revealed a reduction in blood loss when oxytocin was
used in laparoscopic myomectomy (1 RCT, 60 women: MD -
175.50 ml, 95% CI -301.01 to -49.93) but not open abdominal
myomectomy (1RCT, 94women:MD57.00ml, 95%CI -129.22
to 243.22; Analysis 5.1).
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5.2. Need for blood transfusion
Oxytocin did not appear to have an effect on the need for blood
transfusion (2 RCTs, 154 women: OR 0.54, 95%CI 0.03 to 8.51;
I2 = 89%; Analysis 5.2).
Secondary outcomes
5.3. Duration of surgery
Oxytocin had no significant effect on the operating time (2 RCTs,
154women:MD3.5min, 95%CI -1.88 to 8.88; I2 =0%;Analysis
5.3).
5.4. Postoperative hospital stay
Compared to placebo, oxytocin significantly reduced the duration
of postoperative hospital stay (1 RCT, 60 women: MD -0.60 days,
95% CI -1.19 to -0.01; Analysis 5.5).
5.5. Postoperative morbidity
There was no evidence of an effect on postoperative morbidity by
oxytocin compared to placebo (1 RCT, 60 women: OR 1.00, 95%
CI 0.06 to 16.76; Analysis 5.5).
6. Mesna versus placebo
Primary outcomes
6.1. Blood loss
Blood loss was not reported by the investigators (Benassi 2000).
6.2. Need for blood transfusion
The need for blood transfusion was not reported by the investiga-
tors (Benassi 2000).
Secondary outcomes
6.3. Postoperative haemoglobin and haematocrit
Postoperative haemoglobin (1 RCT, 58 women: MD 0.50 g/dl,
95% CI 0.42 to 0.58; Analysis 6.3) and haematocrit (1 RCT, 58
women: MD 1.90%, 95% CI 1.30 to 2.50; Analysis 6.4) were
significantly higher with mesna compared to placebo.
6.4. Duration of surgery
Chemical dissection with mesna was associated with a reduction
in the operating time compared to placebo (1 RCT, 58 women:
MD -20 min, 95% CI -28.64 to -11.36; Analysis 6.1).
6.4. Postoperative morbidity
There was no evidence of an effect on the incidence of postopera-
tive fever by mesna compared to placebo (1 RCT, 58 women: OR
0.14, 95% CI 0.02 to 1.22; Analysis 6.5).
6.5. Length of hospital stay
Mesna was associated with a reduction in length of hospital stay
compared to placebo (1 RCT, 58 women: MD - 1.00 day, 95%
CI -1.12 to -0.88; Analysis 6.2).
7. Myoma enucleation by morcellation versus no
treatment
Primary outcomes
7.1. Blood loss
Myoma enucleation by morcellation did not have a significant
effect on blood loss during laparoscopic myomectomy (1 RCT, 48
women: MD 65.40 ml, 95% CI -36.47 to 167.27; Analysis 7.1).
7.2. Need for blood transfusion
The need for blood transfusion was not reported by the investiga-
tors (Sinha 2005).
Secondary outcomes
7.3. Duration of surgery
Myoma morcellation was associated with a reduction in the oper-
ating time compared to placebo (1 RCT, 48 women: MD -25.30
min, 95% CI -44.23 to -6.37; Analysis 8.3).
7.4. Length of hospital stay
Myomamorcellationdidnot showa significant effect on the length
of hospital stay (1 RCT, 48 women: MD -0.07 days, 95% CI -
0.18 to 0.04; Analysis 7.3).
8. Tranexamic acid versus placebo
Primary outcomes
8.1. Blood loss
Intravenous tranexamic acid reduced blood loss during myomec-
tomy compared to placebo (1 RCT, 100 women: MD -243 ml,
95% CI -460.02 to -25.98; Analysis 8.1).
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8.2. Need for blood transfusion
Tranexamic acid did not have a significant effect on the need for
blood transfusion (1 RCT, 100 women: OR 1.71, 95% CI 0.63
to 4.30; Analysis 8.2).
Secondary outcomes
8.3. Postoperative haemoglobin and haematocrit
There was no evidence of effect by tranexamic acid compared to
placebo on postoperative haemoglobin (1 RCT, 100 women: MD
0.21 g/dl, 95% CI -0.36 to 0.78; Analysis 8.4) and haematocrit (1
RCT, 100 women: MD 1.00%, 95% CI -0.43 to 2.43; Analysis
8.5).
8.4 Duration of surgery
Tranexamic acid was associated with a reduction in the operating
time compared to placebo (1 RCT, 100 women: MD -11 min,
95% CI -21.09 to -0.91; Analysis 8.3).
9. Gelatin-thrombin matrix versus placebo or no
treatment
Primary outcomes
9.1. Blood loss
Compared to no treatment, the application of a gelatin-thrombin
matrix on the uterine incision reduced blood loss during myomec-
tomy (1 RCT, 50 women: MD -545.00 ml, 95% CI -593.26 to -
496.74; low-quality evidence; Analysis 9.1) (Summary of findings
6) and postoperative vaginal blood loss (1 RCT, 50 women: MD
-225.00 ml, 95% CI -254.46 to -195.54; Analysis 9.3).
9.2. Need for blood transfusion
Gelatin-thrombin matrix reduced the need for blood transfusion
compared to no treatment (1 RCT, 100 women: OR 0.01, 95%
CI 0.00 to 0.10; low-quality evidence; Analysis 9.2) (Summary of
findings 6).
Secondary outcomes
9.3. Postoperative haemoglobin and haematocrit
Gelatin-thrombin matrix reduced the drop in haemoglobin after
surgery compared to no treatment (1 RCT, 50 women: MD -2.30
g/dl, 95% CI -2.66 to -1.94; Analysis 9.5).
9.4. Duration of surgery
Gelatin-thrombin was associated with an increase in the operating
time compared to no treatment (1 RCT, 50 women: MD 5.00
min, 95% CI 1.29 to 8.71; low-quality evidence; Analysis 9.4)
(Summary of findings 6).
9.4. Length of hospital stay
Gelatin-thrombin matrix reduced the duration of hospital stay
compared to no treatment (1 RCT, 50 women: MD -2.00 days,
95% CI -2.69 to -1.31; Analysis 9.6).
9.5. Postoperative morbidity
There was no evidence of an effect on postoperative fever by
gelatin-thrombin matrix compared to no treatment (1 RCT, 50
women: OR 0.32, 95% CI 0.01 to 8.25; Analysis 9.7).
10. Ascorbic acid versus no treatment
Primary outcomes
10.1. Blood loss
Compared to no treatment, the administration of ascorbic acid
during myomectomy reduced blood loss (1 RCT, 102 women:
MD -411.46 ml, 95% CI -502.58 to -320.34; P < 0.00001; low-
quality evidence; Analysis 10.1) (Summary of findings 7).
10.2. Need for blood transfusion
There was no evidence that ascorbic acid had an effect on the
need for blood transfusion compared to no treatment (1 RCT,
102 women: OR 0.38, 95% CI 0.11 to 1.32; P = 0.13; very low-
quality evidence).
Secondary outcomes
10.3. Postoperative haemoglobin and haematocrit
There was evidence that, compared to no treatment, ascorbic
acid reduced the drop in postoperative haematocrit (1 RCT, 102
women: MD -0.70%, 95% CI -1.34 to -0.06; P = 0.03) but not
the drop in postoperative haemoglobin (1 RCT, 102 women: MD
0.14 g/dl, 95% CI -0.22 to 0.50; P = 0.44).
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10.4. Duration of surgery
Ascorbic acid reduced the operating time compared to no treat-
ment (1 RCT, 102 women: MD -26.00 min, 95% CI -33.10 to -
18.90; P < 0.00001; low-quality evidence).
10.5. Duration of hospital stay
Compared to no treatment, there was evidence that ascorbic acid
reduced the duration of hospital stay (1 RCT, 102 women: MD -
0.4 days, 95% CI -0.65 to -0.15; P = 0.002).
10.6. Postoperative morbidity
Overall, there was no evidence of an effect on postoperative mor-
bidity by ascorbic acid compared to no treatment (1 RCT, 102
women:OR1.64, 95%CI 0.71 to 3.82; P = 0.25), which included
postoperative fever (OR 1.88, 95% CI 0.58 to 6.07; P = 0.29),
vomiting (OR 1.96, 95% CI 0.17 to 22.32; P = 0.59), constipa-
tion (OR 0.31, 95% CI 0.01 to 7.90; P = 0.48) and severe pain
(OR 2.00, 95 CI 0.36 to 11.44; P = 0.44).
11. Dinoprostone versus placebo or no treatment
Primary outcomes
11.1. Blood loss
Compared to placebo, a dinoprostone vaginal suppository ad-
ministered before myomectomy reduced blood loss (1 RCT, 108
women: MD -131.60 ml, 95% CI -253.42 to -9.78; P = 0.03;
Analysis 11.1).
11.2. Need for blood transfusion
Diniprostone reduced the need for blood transfusion compared
to placebo (1 RCT, 108 women: OR 0.17, 95% CI 0.04 to 0.81;
P = 0.61; low-quality evidence).
Secondary outcomes
11.3. Postoperative haemoglobin and haematocrit
Compared to a placebo, dinoprostone reduced the drop in post-
operative haemoglobin (1 RCT, 108 women: MD -0.50, 95% CI
-0.88 to -0.12; P = 0.009), but had no effect on postoperative
haematocrit (1 RCT, 108 women: MD 0.10, 95% CI -0.39 to
0.59; P = 0.69).
11.4. Duration of surgery
Compared toplacebo, dinoprostone hadno effect on the operating
time (1 RCT, 108 women: MD -2.60 min, 95% CI -12.55 to
7.35; P = 0.25).
11.5. Length of hospital stay
There was no evidence of an effect on the duration of hospital stay
by dinoprostone compared to no treatment (1 RCT, 108 women:
MD 0.30 days, 95% CI -0.22 to 0.82; P = 0.25).
11.6. Postoperative morbidity
There was no evidence of an effect on postoperative fever by dino-
prostone compared to no treatment (OR 1.53, 95% CI 0.25 to
9.54; P = 0.65).
12. Loop ligation of myoma pseudocapsule combined
with vasopressin versus no treatment
12.1. Blood loss
Compared to no treatment, loop ligation of the myoma pseu-
docapsule during myomectomy reduced blood loss (1 RCT, 70
women: MD -305.01 ml, 95% CI -354.83 to -255.19; P <
0.00001; Analysis 12.1).
12.2. Need for blood transfusion
Compared to no treatment, loop ligation of the myoma pseudo-
capsule had no effect on the need for blood transfusion (1 RCT,
70 women: OR 0.08, 95% CI 0.00 to 1.47; P = 0.09).
Secondary outcomes
12.3. Duration of surgery
Loop ligation of the myoma pseudocapsule significantly reduced
the operating time (1 RCT, 70 women: MD -32.76 min, 95% CI
-40.81 to -24.71; P < 0.00001).
12.4. Length of hospital stay
Compared to no treatment, loop ligation of the myoma pseudo-
capsule significantly reduced the duration of hospital stay (1 RCT,
70 women: MD -1.46 days, 95% CI -1.85 to -1.07; P < 0.00001).
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13. Temporary clipping of uterine artery versus no
treatment
13.1. Blood loss
This outcome was not reported by the investigators.
13.2. Need for blood transfusion
No patient required blood transfusion.
Secondary outcomes
13.3. Postoperative haemoglobin and haematocrit
We found no evidence of an effect on postoperative haemoglobin
by the temporary clipping of the uterine artery compared to no
treatment (1 RCT, 166 women: MD -2.25 g/dl, 95% CI -0.61 to
0.11; P = 0.17).
13.4. Duration of surgery
The temporary clipping of the uterine artery significantly increased
the operating time (1 RCT, 166 women: MD 40.00 min, 95% CI
30.01 to 49.99; P < 0.00001).
13.5. Length of hospital stay
We found no evidence of an effect on the duration of hospital stay
by the temporary clipping of the uterine artery compared to no
treatment (1 RCT, 70 women: MD 0.00 days, 95% CI -0.15 to
0.15; P = 1.00).
13.6. Postoperative morbidity
We found no evidence of an effect on postoperative morbidity
by the temporary clipping of the uterine artery compared to no
treatment (1 RCT, 166 women: OR 1.95, 95% CI 0.79 to 4.79;
P = 0.14).
14. Fibrin sealant patch versus no treatment
14.1. Blood loss
Compared to no treatment, the application of a fibrin sealant
patch (surgical collagen patch or sponge coatedwith thrombin and
fibrinogen to stop local bleeding) on the uterus reduced blood loss
during myomectomy (1 RCT, 70 women: MD -26.50 ml, 95%
CI -44.46 to -8.53; P = 0.004; Analysis 14.1) and postoperative
blood loss in the drainage bag (1 RCT, 70 women: MD -44.60
ml, 95% CI -65.06 to -24.14; P < 0.0001).
14.2. Need for blood transfusion
No patient required blood transfusion.
Secondary outcomes
14.3. Pregnancy (if desired)
We found no evidence of an effect on conception after myomec-
tomy by the fibrin sealant patch compared to no treatment (1
RCT, 70 women: OR 3.16, 95% CI 0.76 to 13.11; P = 0.11).
14.4. Duration of surgery
We found no evidence of an effect on the operating time by fibrin
sealant patch compared to no treatment (1 RCT, 70 women: MD
-0.4 min, 95% CI -4.47 to 3.67; P = 0.85).
14.5. Length of hospital stay
We found no effect of the fibrin sealant patch on the duration of
hospital stay (1 RCT, 70 women: MD 0.00 days, 95% CI -0.09
to 0.09; P = 1.00).
15. Other analysis
Where data were available, we performed subgroup analyses based
on the technique of myomectomy (Analysis 1.1; Analysis 1.3;
Analysis 2.1; Analysis 2.2). The use of a random-effects model
compared to a fixed-effect model made no difference. All other
planned subgroup and sensitivity analyses were not conducted due
to insufficient data.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Misoprostol compared to placebo to reduce blood loss during myomectomy for fibroids
Patient or population: Women with fibroids
Settings: Middle and high income countries
Intervention: Misoprostol
Comparison: Placebo
Outcomes Illustrative comparative risks (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Placebo Misoprostol
Blood loss (ml)
Estimated blood loss dur-
ing myomectomy
The mean blood loss in
placebo group was
322.39 ml
The mean blood loss in
misoprostol group was
97.88 ml lower
(125.52 to 70.24 lower)
MD -97.88 (-125.52 to -
70.24)
89
(2 studies)
⊕⊕⊕©
moderate1
We rated down the qual-
ity of evidence (by 1) be-
cause the data were de-
rived from two small stud-
ies and we could not rule
out the possibility of pub-
lication bias
Need for blood transfu-
sion
Number of participants
who received blood trans-
fusion
87 per 1000 31 per 1000
(4 to 217)
OR 0.36
(0.05 to 2.5)
89
(2 studies)
⊕⊕©©
low1
We rated down the qual-
ity of evidence (by 2) be-
cause (i) we could not
conclusively rule out the
possibility of publication
bias and (ii) the pooled ef-
fect had wide confidence
intervals
Duration of surgery
(min)
Operative time
The mean duration of
surgery in placebo group
was
69.57 min for abdomi-
nal myomectomy and 77
min for laparoscopic my-
omectomy
The mean duration of
surgery in misoprostol
group was
9.50 min lower
(15.90 lower to 3.10
lower) in abdominal my-
omectomy and 9 min
MD -9.50
(-15.90 to -3.10) for ab-
dominal myomectomy &
MD 9.00
(-1.63 to 19.63) for la-
paroscopicmyomectomy
25
(1 study) for abdominal
myomectomy &
64
(1 study) for laparoscopic
myomectomy
⊕⊕©©
low1
We rated down the qual-
ity of evidence (by 2) be-
cause (i) we could not
conclusively rule out the
possibility of publication
bias and (ii) the pooled ef-
fect had wide confidence2
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higher (1.63 lower to
19.63 higher) in laparo-
scopic myomectomy
intervals
We did not rate down
the evidence due to het-
erogeneity because this
could be explained by the
type of myomectomy (la-
paroscopy versus laparo-
tomy)
CI: Confidence interval; MD: mean difference; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1In one trial the method of allocation concealment was not reported and in the other trial, allocation concealment was achieved using
sequentially numbered opaque sealed envelopes.
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Vasopressin versus placebo to reduce blood loss during myomectomy for fibroids
Patient or population: Women with fibroids
Settings: Middle and low income countries
Intervention: Vasopressin
Comparison: Placebo
Outcomes Illustrative comparative risks (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Placebo Vasopressin
Blood loss (ml)
Estimated blood loss dur-
ing myomectomy
The mean blood loss in
the placebo groups was
483.09 ml
The mean blood loss in
the vasopressin groups
was
245.87 ml lower
(434.58 to 57.16 lower)
MD -245.87 (-434.58 to
-57.16)
128
(3 studies)
⊕⊕⊕©
moderate1
We rated down the qual-
ity of evidence (by 1)
because the data were
derived from three small
studies and we could not
rule out the possibility of
publication bias
We did not rate down
the evidence due to het-
erogeneity because this
could be explained by
the fact that in one
study women had laparo-
scopic myomectomy and
two other studies, women
has open abdominal my-
omectomy
Need for blood transfu-
sion
Participants who received
blood transfusion
222 per 1000 33 per 1000
(7 to 164)
OR 0.15
(0.03 to 0.74)
90
(2 studies)
⊕⊕⊕©
moderate1
We rated down the qual-
ity of evidence (by 1) be-
cause the data were de-
rived from two small stud-
ies and we could not rule
out the possibility of pub-
lication bias24
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Duration of surgery
Operative time
The mean duration of
surgery in the placebo
groups was
111.45 min
The mean duration of
surgery in the vaso-
pressin groups was
27.72 min lower
(35.82 to 19.61 lower)
MD -27.72 (-35.82 to -
19.61)
108
(2 studies)
⊕⊕⊕©
moderate1
We rated down the qual-
ity of evidence (by 1) be-
cause the data were de-
rived from two small stud-
ies and we could not rule
out the possibility of pub-
lication bias
CI: Confidence interval; MD: mean difference; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1In all the trials, allocation concealment was unclear.
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Bupivicaine plus epinephrine compared to placebo to reduce blood loss during myomectomy for fibroids
Patient or population: Women with fibroids
Settings: University hospital in Italy
Intervention: Bupivicaine plus epinephrine
Comparison: Placebo
Outcomes Illustrative comparative risks (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Placebo Bupivicaine plus
epinephrine
Blood loss (ml)
Estimated blood loss dur-
ing myomectomy
The mean blood loss in
the placebo group was
212.5 ml
The mean blood loss in
the bupivicaine-
epinephrine group was
68.6 ml lower
(93.69 to 43.51 lower)
MD -68.60 (-93.69 to -
43.51)
60
(1 study)
⊕⊕©©
low1
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, with a high risk of
attrition bias (2 patients
in each arm did not re-
ceive assigned interven-
tion because of concomi-
tant disease)
Need for blood transfu-
sion
Participants who received
blood transfusion
Outcome not reported by investigators
Duration of surgery
(min)
Operative time
The mean duration of
surgery in the placebo
group was
109.2 min
The mean duration of
surgery in the bupivi-
caine-epinephrine group
was
30.50 min lower
(37.68 to 23.32 lower)
MD -30.50 (-37.68 to -
23.32)
60
(1 study)
⊕⊕©©
low1
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, with a high risk of
attrition bias (2 patients
in each arm did not re-
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ceive assigned interven-
tion because of concomi-
tant disease)
CI: Confidence interval; MD: mean difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1The allocation concealment was achieved by envelopes containing computer-generated random numbers.
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Peri-cervical tourniquet compared to no treatment to reduce blood loss during myomectomy for fibroids
Patient or population: Women with fibroids
Settings: Low and high income countries
Intervention: Tourniquet around the cervix only, or around both the cervix and the infundibulopelvic ligament
Comparison: No treatment
Outcomes Illustrative comparative risks (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
No treatment Peri-cervical tourniquet
Blood loss (ml)
Estimated blood loss dur-
ing myomectomy
The mean blood loss in
the control groups was
756.4 ml (for cervical
tourniquet) &2359.0 ml
(for cervical plus in-
fundibulopelvic ligament
tourniquet)
The mean blood loss in
the intervention groups
was
240.70 ml lower
(359.61 ml lower to 121.
79 ml lower) for the cer-
vical tourniquet study &
1870 ml lower (2547.
16 ml lower to 1192.84
ml lower) for the cervical
plus infundibulopelvic lig-
ament tourniquet study
MD -240.70 (-359.61
to -121.79) for cervical
touniquet study & -1870
(-2547.16 to -1192.84)
for the cervical plus in-
fundibulopelvic ligament
tourniquet study
121
(2 studies)
⊕⊕©©
low1
We rated down the qual-
ity of evidence (by 2) be-
cause the data were de-
rived from two small stud-
ies that were not pooled
together due to significant
clinical and statistical het-
erogeneity
One study used
polyglactin suture round
both the cervix and in-
fundibulopelvic ligament,
while the other used a
Foley catheter round the
cervix
Need for blood transfu-
sion
Participants who received
blood transfusion
539 per 1000 for cer-
vical tourniquet study &
786 per 1000 for cervical
plus infundibulopelvic lig-
ament study
204 per 1000
for cervical tourniquet
study &71 per 1000 for
cervical plus infundibu-
lopelvic ligament study
OR 0.22
(0.09 to 0.55) or cervical
tourniquet study &
OR 0.02
(0.00 to 0.23) for cervical
plus infundibulopelvic lig-
ament study
121
(2 studies)
⊕⊕©©
low1
We rated down the qual-
ity of evidence (by 2) be-
cause the data were de-
rived from two small stud-
ies which were not pooled
together because of sig-
nificant heterogeneity
One study used
2
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polyglactin suture round
both the cervix and in-
fundibulopelvic ligament,
while the other used a
Foley catheter round the
cervix
Duration of surgery
(min)
Operative time
The mean duration of
surgery in the control
groups was
118 min
The mean duration of
surgery in the intervention
groups was
4 min lower
(29.28 lower to 21.28
higher)
MD -4.00
(-29.28 to 21.28)
28
(1 study)
⊕©©©
very low
We rated down the qual-
ity of evidence (by 3)
because the data were
derived from one small
study and the effect esti-
mate was imprecise
CI: Confidence interval; MD: mean difference; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1In one trial the allocation concealment was unclear and in the other trial allocation concealment was achieved by sealed sequentially-
numbered opaque envelopes containing computer-generated random numbers.
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Gelatin-thrombin matrix compared to placebo or no treatment to reduce blood loss during myomectomy for fibroids
Patient or population: Women with fibroids
Settings: University teaching hospital in Spain
Intervention: Gelatin-thrombin matrix
Comparison: Placebo or no treatment
Outcomes Illustrative comparative risks (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Placebo Gelatin-thrombin matrix
Blood loss (ml)
Estimated blood loss dur-
ing myomectomy
The mean blood loss in
placebo groups was
625 ml
The mean blood loss in
intervention groups was
545 ml lower
(593.26 to 496.74 lower)
MD -545.00 (-593.26 to
-496.74)
50
(1 study)
⊕⊕©©
low1
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, and it is unclear if
outcome assessors were
blind
Need for blood transfu-
sion
Participants who received
blood transfusion
400 per 1000 4 per 1000
(0 to 40)
OR 0.01
(0 to 0.1)
50
(1 study)
⊕⊕©©
low1
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, it is unclear if
outcome assessors were
blind, and the effect esti-
mate was imprecise
Duration of surgery
(min)
Operative time
The mean duration of
surgery in placebo group
was
60 min
The mean duration of
surgery in intervention
group was
5.00 min higher
(1.29 to 8.71 higher)
MD 5.00
(1.29 to 8.71)
50
(1 study)
⊕⊕©©
low1
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, it is unclear if
outcome assessors were
blind, and the effect esti-
mate was imprecise3
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CI: Confidence interval;MD: Mean difference; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Allocation concealment not reported.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Ascorbic acid compared to placebo or no treatment to reduce blood loss during myomectomy for fibroids
Patient or population: Women with fibroids
Settings: Tertiary hospital in Iran
Intervention: Ascorbic acid
Comparison: No treatment
Outcomes Illustrative comparative risks (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
No treatment Ascorbic acid
Blood loss (ml)
Estimated blood loss dur-
ing myomectomy
The mean blood loss in
the control group was
932.9 ml
The mean blood loss
in the intervention group
was
411.46 ml lower
(502.58 to 320.34 lower)
MD -411.46
(-502.58 to -320.34)
102
(1 study)
⊕⊕©©
low1
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, and it is unclear
how allocation conceal-
ment was done
Need for blood transfu-
sion
Participants who received
blood transfusion
180 per 1000 68 per 1000
(20 to 238)
OR 0.38
(0.11 to 1.32)
104
(1 study)
⊕©©©
very low1
We rated down the
quality of evidence (by
2) because the data
were derived from one
small study, it is unclear
how allocation conceal-
ment was done, and the
estimate was imprecise
Duration of surgery
(min)
Operative time
The mean duration of
surgery in the control
group was
68 min
The mean duration of
surgery in the intervention
group was
26.00 min lower
(33.1 to 18.9 lower)
MD -26.00
(-33.10 to -18.90)
102
(1 study)
⊕⊕©©
low1
We rated down the qual-
ity of evidence (by 2)
because the data were
derived from one small
study, and it is unclear
how allocation conceal-
ment was done
3
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CI: Confidence interval; MD: Mean difference; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Allocation concealment not reported.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
This review has evaluated the effect of different interventions on
blood loss during myomectomy for uterine fibroids. There are a
few well designed randomised trials that have assessed the effect of
each intervention on blood loss. Compared to placebo or no treat-
ment, misoprostol, vasopressin, bupivacaine plus epinephrine,
tranexamic acid, gelatin-thrombin matrix, peri-cervical tourni-
quet, tourniquet round both cervix and infundibulopelvic liga-
ment, mesna, ascorbic acid, dinoprostone, loop ligation of the
myoma pseudocapsule and a fibrin sealant patch (collagen sponge
with thrombin and fibrinogen) were found to significantly re-
duce bleeding duringmyomectomy. In contrast, oxytocin, myoma
morcellation and temporary clipping of the uterine artery did not
significantly reduce blood loss when compared to placebo or no
treatment.
Utero-tonics
Some interventions have shown promising effects on reducing
blood loss during myomectomy. Both misoprostol (MD -97.88
ml, 95% CI -125.52 to -70.24) and dinoprostone (MD -131.60
ml, 95% CI -253.42 to -9.78), prostaglandin E2 analogues, were
shown to significantly reduce blood loss, probably by causing uter-
ine contraction and reducing uterine blood flow. The trials on
oxytocin, a known utero-tonic agent, showed no statistically sig-
nificant effect on blood loss during myomectomy.
Pharmacologic manipulation of the coagulation
cascade
Similarly to prostaglandin E2 analogues, tranexamic acid (MD -
243 ml, 95% CI -460.02 to -25.98) was found to significantly
reduce blood loss during myomectomy. Tranexamic acid is an an-
tifibrinolytic agent that acts by blocking the lysine-binding site on
plasmin thereby inhibiting fibrinolysis, the process wherein a fib-
rin clot, the product of coagulation, is broken down. Tranexamic
acid has been used in clinical settings since the 1960s and has been
found to reduce blood loss and the need for blood transfusion
in cardiac surgery, liver transplantation and orthopaedic surgery
(Dunn 1999).
The application of gelatin-thrombin haemostatic sealant (MD -
545.00 ml, 95% CI -593.26 to -496.74), a matrix of cross-linked
bovine-derived gelatin granules and a bovine-derived thrombin
component, on the site of uterine incision significantly reduced
blood loss during surgery and the need for blood transfusion. The
gelatin matrix is hydrophilic and therefore adheres very well to
wet tissue. Thematrix activates the coagulation cascade and causes
haemostasis.
The application of a fibrin sealant patch (MD -26.50 ml, 95%
CI -44.47 to -8.53), which is a surgical patch coated with human
coagulation factors fibrinogen and thrombin, significantly reduced
blood loss during myomectomy.
Ascorbic acid (MD -411.46 ml, 95% CI -502.58 to -320.34)
significantly reduced blood loss during myomectomy. Ascorbic
acid (vitamin C) has important functions in platelets. During the
first phase of haemostasis platelets are activated and aggregate to
form a haemostasis plug. Ascorbic acid is water-soluble and is
not stored in the body, and when depleted the bleeding tendency
increases due to dysfunctional connective tissue production in the
blood vessel wall.
Interventions on the uterine artery
We found a significant reduction in intraoperative blood loss when
vasopressin (MD -245.87 ml, 95% CI -434.58 to -57.16) is in-
jected into the uterine muscles overlying the myoma during my-
omectomy. The injection of bupivacaine plus epinephrine into the
myometrium overlying themyomawas evaluated in one study and
the result showed evidence of a reduction in blood loss, although
this might not be clinically significant (68.6 ml). Both vasopressin
and bupivacaine plus epinephrine are known local vasoconstric-
tors and may reduce local blood flow when injected around the
myoma.
A peri-cervical tourniquet and use of a tourniquet round both
the cervix and the infundibulopelvic ligament also significantly re-
duced blood loss during myomectomy, as anticipated. The uterus
receives its blood supply primarily from the uterine artery and the
occlusion of the uterine artery is expected to reduce blood loss by
reducing blood flow to the uterus.However, there is no evidence
that temporary clipping of the uterine artery reduce blood loss.
Chemical dissection of myoma
The study on the effect of chemical dissection of the myoma with
mesna did not directly evaluate blood loss but showed a signif-
icant gain in postoperative haemoglobin levels. Mesna is a lytic
agent that can disrupt connections between tissue layers (Denaro
2001) and may thus facilitate myoma enucleation. Similarly, we
found that loop ligation of the myoma pseudocapsule during la-
paroscopic myomectomy significantly reduced blood loss.
Other outcomes
One way of evaluating the difficulties encountered during my-
omectomy was by measuring the operating time. Trials on vaso-
pressin, bupivacaine plus epinephrine, mesna, tranexamic acid,
ascorbic acid, myoma enucleation by morcellation, and loop liga-
tion of the myoma pseudocapsule recorded a significant reduction
in operating time. The use of misoprostol, oxytocin, peri-cervical
tourniquet, dinoprostone and a fibrin sealant patch showed no
evidence of effect on the duration of surgery. The use of a gelatin-
thrombin matrix and the temporary clipping of the uterine artery
increased the operating time.
34Interventions to reduce haemorrhage during myomectomy for fibroids (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Postoperative outcome was assessed by the duration of hospitali-
sation. A few trials included the duration of hospital stay in their
evaluations. The trials on mesna, gelatin-thrombin matrix, ascor-
bic acid and loop ligation of the myoma pseudocapsule recorded a
significant decrease in the duration of hospital stay. No other trials
found a significant effect on the duration of hospitalisation.
Overall completeness and applicability of
evidence
Most comparisons included few trials with small sample sizes and
insufficient power to detect moderate differences in blood loss.
This review assessed only the effects of interventions versus placebo
or no treatment. Head-to-head comparisons were not assessed by
the review.
There are insufficient data on the adverse effects and costs of the
different interventions. The trials on the gelatin-thrombin matrix
and ascorbic acid showedno significant difference in adverse effects
between the intervention and the control groups. Most trials that
commented on the adverse effects simply stated that there were no
such effects recorded in the trial. Knowledge of these adverse events
and the tolerability of the interventions is important because we
have to make a trade off between the estimated benefits and the
harms and costs before making any appropriate decisions about
use or non-use of any intervention. Nevertheless, evidence from
clinical practice has shown that mesna is well tolerated and can be
taken orally (Burkert 1983).
Quality of the evidence
The methodological quality of the included studies was generally
good. The trials had small sample sizes (and, therefore, the effect
sizes had large confidence intervals) and there was heterogeneity of
effect between the included trials with several of the interventions.
Despite the small sample sizes and heterogeneity of effect, there
was a significant reduction in blood loss duringmyomectomywith
10 interventions when compared to placebo or no treatment.
• Misoprostol and vasopressin: we rated each as moderate
quality evidence because with both interventions the data were
derived from two small studies and we could not rule out the
possibility of publication bias.
• Tranexamic acid, fibrin sealant patch, dinoprostone,peri-
cervical tourniquet and use of a tourniquet round both the cervix
and the infundibulopelvic ligament : we rated each as low quality
evidence because the data from each of the interventions were
derived from one or two small studies and the pooled effect
estimate was imprecise.
• Ascorbic acid and loop ligation of myoma pseudocapsule:
we rated each as low quality of evidence because with both
interventions the data were derived from one small study and it
was unclear how allocation concealment was done.
• Bupivacaine plus epinephrine: we rated this as low quality
evidence because the data were derived from one small study
with a high risk of attrition bias (two patients in each arm did
not receive the assigned intervention because of concomitant
disease).
• Gelatin-thrombin matrix: we rated this as low quality
evidence because the data were derived from one small study and
it was unclear if the outcome assessors were blind.
Potential biases in the review process
Publication and selection biases are potential threats to all system-
atic reviews. We are confident that we have identified the exist-
ing clinical trials relevant to our question but cannot rule out the
possibility that there are additional trials that are unpublished or
published in sources not accessible to our search.
Agreements and disagreements with other
studies or reviews
We are not aware of any reviews that have assessed the effec-
tiveness of interventions to reduce haemorrhage during myomec-
tomy. Evidence from this review supports findings previously re-
ported in non-randomised studies (McLaughin 1985; Baldoni
1995; Hutchins 1996; Dimitrov 1999).
The use of oxytocin showed no evidence of an effect on blood loss
during myomectomy. This is consistent with other evidence that
the myometrial concentration of oxytocin receptors is very low in
non-pregnant uteri (Fuchs 1984).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently, there is moderate-quality evidence that misoprostol
(MD -97.88 ml, 95%CI -125.52 to -70.24) and vasopressin (MD
-245.87 ml, 95%CI -434.58 to -57.16), and low-quality evidence
that bupivacaine plus epinephrine (MD-68.60ml, 95%CI -93.69
to -43.51), gelatin-thrombin matrix (MD -545.00 ml, 95% CI
-593.26 to -496.74), tranexamic acid (MD -243 ml, 95% CI -
460.02 to -25.98), peri-cervical tourniquet (MD-240.70ml. 95%
CI -359.61 to 121.7),tourniquet round both the cervix and the
infundibulopelvic ligament (MD 1870.00 ml, 95% CI -2547.16,
to -1192.84), ascorbic acid (MD -411.46 ml, 95% CI -502.58 to
-320.34), dinoprostone (MD -131.60 ml, 95% CI -253.42 to -
9.78), loop ligation of the myoma pseudocapsule (MD -305.01
ml, 95% CI -354.83 to -255) and a fibrin sealant patch (MD -
26.50, 95%CI -44.47 to -8.53) may reduce blood loss during my-
omectomy. However, since we did not include trials with head-
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to-head comparisons, we cannot draw any conclusions about the
superiority of one intervention over the other. Due to the small
reduction in blood loss (< 70 ml), the use of bupivacaine plus
epinephrine and a fibrin sealant patch have limited clinical im-
portance. At present there is no evidence that oxytocin, myoma
enucleation by morcellation, and the temporary clipping of uter-
ine arteries during myomectomy have an effect on intraoperative
blood loss.
Implications for research
There is a need for well designed randomised controlled trials
to shed more light on the effectiveness of different interventions
in reducing blood loss during myomectomy. To date, a few ran-
domised trials, often will small sample sizes, have addressed this
issue and so there is a need to fill the current gap of knowledge
which has very important practical implications. Apart from the
effectiveness, data on the cost-effectiveness, future pregnancy (if
desired), and adverse effects of different interventions are lacking.
This is important for clinical decision making since such decisions
are based on trade offs between benefits on the one hand and costs
and adverse events on the other.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agostini 2005
Methods Single centre study. Described as randomised, but no details on how patients were
allocated to trial interventions
Patients, care providers, and outcome assessors were blinded to treatment allocation
Power calculation performed
No losses to follow up, and all patients were analysed in groups to which they were
assigned
Source of funding not mentioned
Participants Setting: university hospital in Marseille, France
Inclusion criteria: patients with uterine myoma who required abdominal or vaginal
myomectomy
Exclusion criteria: preoperative embolisation and preoperative administration of any
GnRh analogue
n = 94
Mean age: 40 years (SD 5.2) in the treatment group and 39 years (SD 4.3) in the placebo
group
Ethnicity: not described
Sizes of the fibroids: no significant difference in the weight and number of myomas
between the treatment and control groups
Interventions Treatment arm (n = 47): 15 IU oxytocin administered by an IV infusion of 125cm3 of
physiological serum over 30 min, beginning at the start of uterine incision
Control group (n = 47): physiological serum (placebo) administered in place of oxytocin
Type of operation: laparotomy or vaginal route
Outcomes Perioperative blood loss, blood transfusion, and duration of surgery
Blood loss was estimated using both the blood aspirated into the canisters, minus the
irrigant, and the blood absorbed in the lap sponges
Notes Indications for myomectomy: bleeding, pelvic pain, and fertility
Authors not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no details on
how patients were allocated to trial inter-
ventions
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
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Agostini 2005 (Continued)
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both participants and care providers were
blinded to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded to treat-
ment allocation
Assaf 1999
Methods Single centre study. Patients allocated to trial interventions using a random numbers
table (but no description is given of how the table was generated)
Neither patients nor care providers were blinded
Power calculation: not done
No losses to follow up, and all patients were analysed in groups to which they were
assigned
Source of funding: not mentioned
Participants Setting: university hospital in Cairo, Egypt
Inclusion criteria: infertile patients with fewer than 3 myomas, the largest of which
was less than 7 cm, myoma on the anterior wall, subserous-interstitial myoma, and no
procedure other than myomectomy required
Exclusion criteria: posterior myoma, subserous myoma only, myoma smaller than 3 cm,
operative procedures in addition to myomectomy
n = 38
Mean age: 33.4 years (SD 2.2) in both groups
Ethnicity: not described
Myoma sizes: 30-70 mm
Interventions Treatment arm (n = 21): ornipressin injection (5IU) diluted in 100 ml saline was injected
to form 2 to 3 weals in the base of the myomas, immediately prior to incision of the
uterine capsule
Control group (n = 17): no treatment offered
All patients had second-look laparoscopy 1 month after the original procedure and were
then followed up for 1 year
Type of operation: laparotomy
Outcomes Perioperative blood loss, operation time, hospital stay, adhesions, and pregnancy outcome
Notes Indications for myomectomy: infertility after excluding all other causes except fibroid
Authors not contacted
Risk of bias
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Assaf 1999 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients allocated to trial interventions us-
ing a random numbers table (but no de-
scription is given of how the table was gen-
erated)
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither patients nor care providers were
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unblinded
Benassi 2000
Methods Single centre study
Allocation to interventions using computer-generated random numbers
Patients blinded, but assessors unblinded
Power calculation: not done
No losses to follow up, and all patients were analysed in groups to which they were
assigned
Source of funding: not mentioned
Participants Setting: university hospital, Parma, Italy
Inclusion criteria: patients with symptomatic fibroids (menorrhagia, pelvic pain, and
compression)
Exclusion criteria: use of hormonal substances within 6 months proceeding myomec-
tomy, previous uterine surgery, pelvic inflammatory diseases
n = 58
Age range: 25-45 years
Ethnicity not described
Size of myomas: 2-17 cm
Interventions Treatment group (n = 29): use of sodium-2-mercaptoethane sulfonate (mesna) for chem-
ical dissection (removal of fibroids with the aid of a chemical substance that breaks down
tissues) of myoma during myomectomy
Control group (n = 29): use of saline for dissection of myomas
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Benassi 2000 (Continued)
Type of operation: laparotomy
Outcomes Postoperative haemoglobin and haematocrit, duration of operation, hospital stay, and
postoperative complications
Notes Indications for myomectomy: menorrhagia, pelvic pain, and compression
Authors not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation to interventions using com-
puter-generated random numbers
Allocation concealment (selection bias) Low risk Adequate
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors unblinded
Caglar 2008
Methods Single centre study
Patients were randomised according to a computer-generated sequence
Participants allocated into groups by sequentially numbered drug containers of identical
appearance
Patients, surgeons and anaesthesiologists were blinded
Power calculation: performed
No losses to follow up and all patients were analysed in the group in which they were
allocated
No details given about the source of funding
Participants Setting: Ankara Etlik Maternity and Women’s Health Teaching Research Hospital,
Ankara, Turkey
Inclusion criteria: participants were women scheduled for myomectomy due to myoma
uteri
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Caglar 2008 (Continued)
Exclusion criteria: patients with malignancy, history of thromboembolic disease, is-
chaemic heart disease, subarachnoidal bleeding, hematuria, and body mass index >30
were excluded
n = 100
Age: mean age of the patients was 35.3 ± 5 years (range 23 to 40)
Ethnicity: not described
Total volume of myomas: 457cm3 (SD = 669) in the intervention group and 286cm3
(SD = 259) in the control group
Interventions Treatment arm (n = 50): a bolus intravenous injection of tranexamic acid (a medication
that prevents bleeding by inhibiting the breakdown of blood clots) 10mg/kg (maximum
1g) 15 min before incision followed by continuous infusion of 1mg/kg/h dissolved in 1
L of saline for 10 h (maximum 1 g/10 h)
Control arm (n = 50): a bolus injection of placebo (saline of similar volume to tranexamic
acid) 15 min before incision followed by continuous infusion of 1 L of saline for 10 h
Type of operation: laparotomy
Outcomes Perioperative blood loss, postoperative blood loss, total blood loss, duration of surgery,
postoperative haemoglobin, postoperative haematocrit, blood transfusion requirements
on ward
Notes Authors contacted
No significant difference in the baseline characteristics such as age, body mass index,
bleeding time, coagulation time, prothrombin time, the number and volume of myomas
removed between the intervention and control groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised according to a
computer-generated sequence
Allocation concealment (selection bias) Low risk Participants allocated into groups by se-
quentially numbered drug containers of
identical appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel were blinded
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Caglar 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded
Celik 2003
Methods Single centre study
Described as randomised, but no details on how patients were allocated to trial inter-
ventions
Both patients, care providers, and outcome assessors were blinded to treatment allocation
Power calculation: performed
No losses to follow up, and all patients were analysed in groups to which they were
assigned
Source of funding: not mentioned
Participants Setting: university hospital, Elazig, Turkey
Inclusion criteria: symptomatic uterine fibroids scheduled for myomectomy
n = 25
Mean age: 31.7 years (SD 4.4) in the treatment arm and 32.2 years (SD 2.9) in the
placebo group
Ethnicity: not mentioned
Interventions Treatment arm (n = 13): 400 uG misoprostol administered vaginally 1 hour before
surgery
Control arm (n = 12): placebo of identical shape and colour
Sizes of fibroids: mean diameter of myomas 150.7 mm (SD 28.6) in the treatment arm
and 154.2 mm (SD 24.7) in the control arm
Type of operation: laparotomy
Outcomes Perioperative blood loss, postoperative haemoglobin, operation time, blood transfusion,
hospital stay, and postoperative morbidity
Blood loss determined by aspiration equipment during the operation
Notes Indication for myomectomy: symptomatic uterine fibroid
Authors not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no details on
how patients were allocated to trial inter-
ventions
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
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Celik 2003 (Continued)
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both participants and personnel were
blinded to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded to treat-
ment allocation
Frederick 1994
Methods Single centre study
Randomisationby drawingnumbers fromabox.The numbers ranged from1 to20:when
an odd number was drawn the patient received vasopressin, whereas an even number
resulted in placebo being given
Patients, care providers, and outcome assessors were blinded
Power calculation: performed but study stopped half-way and the code broken because
of heavy bleeding in 10 patients
No losses to follow up, and all patients were analysed in groups to which they were
assigned
Source of funding: not mentioned
Participants Setting: university hospital, Kingston, Jamaica
Inclusion criteria: symptomatic uterine myoma at least size of 14 weeks gestation
Exclusion criteria: contraindication to vasopressin (notably cardiovascular and respiratory
diseases)
n = 20
Median age: 32 years (range 24-40)
Ethnicity: not described
Sizes of fibroids: 5.3-14.0 cm
Interventions Treatment (n = 10): injection into the broad ligaments of 20 units/ml of vasopressin (i.
e. 1ml diluted in 19 ml saline) made up at the time of surgery
Control: n = 10, Injection of placebo (20 ml normal saline)
Type of operation: laparotomy
Outcomes Perioperative blood loss, blood transfusion
Notes Indications for myomectomy: menorrhagia, recurrent miscarriage, subfertility
Authors not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
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Frederick 1994 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation by drawing numbers from
a box
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded
Ikechebelu 2010
Methods Single study centre. Patients were randomly allocated to either the control group (n =
39), or the intervention group (n = 54). The method of randomisation is not mentioned.
Informed consent was obtained in all cases before the procedure
Power calculation: Not done
Loss to follow up: There was no loss to follow up and all patients were analysed in the
group in which they were allocated
Participants Setting: Tertiary University Teaching hospital in Nigeria
Inclusion criteria: Not stated
Exclusion criteria: Not stated
Mean age: The mean age of patients was 35 years (standard deviation 6.1 years). The
mean age was similar in the two groups
Ethnicity: Not mentioned
Myoma: 83.9% were intramural, 53.8% were subserous and 33.0% were submucous.
There was no significant difference with regards to fibroid location
Interventions Treatment group (tourniquet): Foley catheter was used as an improvised tourniquet
applied to the base of the uterus close to the insertion of the uterosacral ligaments. The
Fallopian tubes and the ovaries were carefully excluded from the line of the tourniquet
to avoid direct compression and necrosis. The tourniquet was released intermittently (at
about 30 minutes interval) during the surgery and finally removed after the repair of the
uterus
Control group (no tourniquet): Myomectomy was performed without the use of any
uterine clamp or improvised tourniquet
Type of operation: Laparotomy
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Ikechebelu 2010 (Continued)
Outcomes Blood loss, transfusion rate, and postoperative complications
Notes Authors not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It is unclear how the authors generated the
random sequence
Allocation concealment (selection bias) Unclear risk Allocation concealment is not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was no incomplete outcome data
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The control group receive no treatment,
rather than placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if outcome assessors were blinded
Kalogiannidis 2011
Methods Randomised controlled trial with 30 participants assigned to group I (misoprostol group)
and 34 participants assigned to group II (placebo group)
Prospective randomised trial performed among women scheduled from February 2007
and February 2009
Setting: Hospital in Greece
Power calculation performed
No loss to follow up
Participants Inclusion criteria: menstruating women aged ≤ 45 years, with three or less myomas
of diameter ranging between 30mm and 90mm. Patients with cervical or endometrial
pathology as well as with adnexal masses were excluded
Intervention group: mean age of 37.2 years (SD = 6.5) and control group: mean age of
34.8 years (SD = 4.6)
Ethnicity not reported
Intervention group: n = 30
Control group: n = 34
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Kalogiannidis 2011 (Continued)
Interventions Intervention group received 400mg intravaginal misoprostol 1hr before surgery and the
control group received intravaginal placebo 1hr before surgery. The intravaginal placebo
was ‘similar’ to the misoprostol. All patients had laparoscopic myomectomy
Outcomes Outcomes measured included postoperative Hb, postoperative anaemia, blood transfu-
sion, duration of the operation, side-effects, and blood loss. Blood loss was estimated
as the difference between the irrigated and aspirated liquid from the peritoneal cavity
during the operation (no gauze was used)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants described as ‘randomly’ al-
located to the intervention and control
groups, but no details given
Allocation concealment (selection bias) Low risk Allocation concealment was achieved using
sequentially numbered opaque sealed en-
velopes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data reported
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both participants and health personnel
were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded
Leone Maggiore 2011
Methods Randomised controlled trial with 70 participants randomised: 35 participants to Group
A (Tachosil group) and 35 participants to Group B (no treatment group)
Setting: Italy
Participants Patients of reproductive age with intramural uterine fibroids
Inclusion criteria: only patients with diagnosis of intramural fibroids via ultrasound
where the distance between the deepest part of the fibroid and the endometrium is ≥0.
5cm
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Leone Maggiore 2011 (Continued)
Exclusion criteria: women with >3 fibroids, subserosal or submucosal fibroids, fibroid
diameter >10cm, use of hormonal treatments in the 6 months before surgery, previous
uterine surgery, any pathology requiring further surgical treatment, BMI ≥ 29, women
with contraindications to general anaesthesia, or any women with a psychiatric condition
that prevents informed consent
Ethinicity not reported
Interventions All myomectomies were done laparoscopically
Participants of the intervention group were administered fibrin sealant patch called
Tachosil i.e. collagen sponge with thrombin and fibrinogen used to stop local bleeding
on internal organs (n=35)
The control group received no additional treatment (n=35)
Time required to apply the Tachosil was measured
The median number of Tachosil used on each patient was 1 with a range of 1-3
Outcomes The outcomes measured included the postoperative complications, volume of blood
collected intraoperatively, volume of blood in drainage bag, No. of days with drainage
bag and No. of days of hospitalisation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by a “computer-generated
list”
Allocation concealment (selection bias) Low risk A statistician with no role in the study as-
signed the groups into sealed, opaque en-
velopes in sequential order
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was no loss to follow up
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Control group had no treatment rather
than a placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A researcher who did not know to
which group the patients were randomised,
recorded the post-op complications, vol-
ume of blood in the drainage bag, and the
no. of days the drainage bag was used
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Pourmatroud 2012
Methods Randomised controlled trial involving 102 participants: 52 participants in received ascor-
bic acid and 50 participants received no treatment
Setting: Tertiary hospital in Ahvaz, Iran
From October 2009 to August 2010, women (n = 102) of reproductive age who were
admitted for an abdominal myomectomy were randomly assigned to receive either ascor-
bic acid to no treatment
No power calculation performed
Participants At least one non-cavitary fibroma ≥ 40 mm2 in size; a normal coagulation profile; non-
smoker; no history of chronic illness (renal failure, drug abuse, haemoglobinopathy or
respiratory, liver or heart disease); no history of recent hospitalization; regular consump-
tion of fresh fruit or vegetables at least once a day and no history of glucose 6-phophatase
dehydrogenase deficiency. Baseline characteristics were similar in both groups
Ethnicity not described
Interventions Intervention group received ascorbic acid 500mg in 15ml normal saline at a rate of 50ug/
min, first ampoule of 500mg ascorbic acid given after reaching the uterus and before
myomectomy, the second administered during myoma enucleation and the third during
wound closure. After the operation, two additional ascorbic acid ampoules were infused
at a rate of 20ug/min over the first 12h. Control group received no treatment. In both
groups, myomectomy was performed by laparotomy
Outcomes The outcomes measured were the size and number of myoma, duration of the operation,
blood loss, haemoglobin and haematocrit 6h after the operation, blood transfusion, and
other complications. Blood loss was measured by adding the blood collected via suction
with the number of soaked surgical 4X4 gauze (each one assigned a value of 5 ml blood)
and towels (each one was assigned a value of 50 ml blood)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants described as ‘randomly as-
signed’ to the intervention and control
groups. No details given on the method of
random sequence generation
Allocation concealment (selection bias) Unclear risk No details given on the method of alloca-
tion concealment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
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Pourmatroud 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It is described that the surgical team was
blinded, but no information given on the
blinding of study participants. However
the control group did not receive an iden-
tical placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Raga 2009
Methods Single study centre. Patients were randomly allocated to either the control group (n =
25), or the intervention group (n = 25) according to a computer-generated sequence.
Informed consent was obtained in all cases according to the local ethics committee
Power calculation: not done
Loss of follow up: there was no loss to follow up and all patients were analysed in the
group in which they were allocated
Participants Setting: Tertiary University Teaching Hospital in Spain
Inclusion criteria: symptomatic fibroids with uterine size greater or equal to 16 weeks
gestation, and a request to retain their uterus
Exclusion criteria: history of bleeding disorder, concurrent anticoagulant therapy, a hae-
moglobin level less than 10g/dl at the time of surgery, and pre-malignant endometrial
histologic findings
Mean age: the mean age of patients was 32 years (range 24-35 years)
Ethnicity: not mentioned
Myoma: mean number of fibroids per patient was 3.1 in the control and 3.2 in the
intervention group. The mean uterine size was 17.9cm in the control group and 18.2cm
in the intervention group
Interventions Treatment group: gelatin-thrombin matrix (Floseal Matrix, Baxter: a substance that
activates the clotting process and stops bleeding) was delivered to the site of the uterine
bleeding (wound) via a single-barrel syringe and a special applicator tip according to the
manufacturers instruction, before closure
Control group: isotonic sodium chloride solution was placed in the uterine bleeding site
before closure
Diluted vasopressin (1:60) was injected into the myometrium around the myoma and
into the myoma tissue in both groups
Type of operation: Laparotomy
Outcomes Operative time, blood loss, intraoperative and postoperative complications, and duration
of hospital stay
Notes Authors not contacted
Risk of bias
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Raga 2009 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly allocated according
to a computer generated sequence
Allocation concealment (selection bias) Unclear risk Allocation concealment is not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Isotonic sodium chloride solution as
placebo was placed in the uterine bleeding
site before closure
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Informationonblinding of outcome assess-
ment not provided
Shokeir 2013
Methods Randomised controlled trial with 54 participants assigned to receive a single dose of
intravaginal 20mg dinoprostone and 54 participants received a placebo
Setting: Mansoura University Hospital in Egypt
Power calculation performed
Participants Women with uterine leiomyomas. Exclusion criteria were any contraindication to dino-
prostone, a known history of pelvic/ovarian endometriosis, a known history or active
medical disease, a known history of previous myomectomy, women who had preopera-
tive mifepristone, GnRH analogue or oral contraceptive pills, women with mental im-
pairment or incompetent in giving consent and women who did not wish to participate
in the study
Ethnicity not reported
Interventions The intervention group received 20mg dinoprostone (prostaglandin E2 analogue, medi-
cations that arrest bleeding by causing contraction of muscles of the uterus) vaginal sup-
pository before the operation. The control group received intravaginal placebo tablet of
the same size and shape as dinoprostone. All patients had open abdominal myomectomy
Outcomes The primary outcome was blood loss and the secondary outcome measures were blood
transfusion, change in Hb level, and incidence of side effects. Blood loss was estimated
by measuring the amount of blood accumulated in the aspiration equipment and the
amount of blood on the surgical gauze using alkaline hematin technique
Notes
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Shokeir 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were assigned serial numbers and
were allocated through a stratified ran-
domisation according to the surgeons. Ran-
dom sequence was generated by computer
in blocks of four
Allocation concealment (selection bias) Low risk Group assignment was put into sealed,
opaque envelopes. After recruitment the
envelope was opened by the research nurse
not involved in the project
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no incomplete data; No loss of
follow up
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and the personnel were
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded
Sinha 2005
Methods Single centre study
Allocation by computer-generated random numbers
Unblinded
Power calculation: not performed
8.3% (4/48) patients excluded because of difficulties which led to them receiving the
treatment of the intervention arm and not the control arm as randomised
Intention-to-treat analysis: not performed
Source of funding: not mentioned
Participants Setting: private endoscopy centre, Mumbai, India
Inclusion criteria: uterus larger than 12 weeks on bimanual examination, ultrasound
confirmation of presence of at least one myoma 7 cm or greater and/or presence of three
or more myomas greater than 5 cm in size
Exclusion criteria: submucosal myoma, associated ovarian lesions or other pathology
discovered by ultrasound exam, a history of surgery
n = 48
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Sinha 2005 (Continued)
Mean age: 32.95 years (SD 4.65) in treatment arm and 33.8 years (SD 6.35) in control
arm
Ethnicity: not described
Sizes of myomas: the mean size of the myoma was 7.6 cm (SD 4.2) in treatment arm
and 7.6 cm (SD 4. 5) in the control arm
Interventions Treatment arm (n = 24): enucleation of myoma by morcellation while still attached to
uterus
Control arm (n = 20): conventional technique of complete enucleation followed by
morcellation
Type of operation: laparoscopy
Outcomes Perioperative blood loss, hospital stay, and length of surgery
Perioperative blood loss estimated by consistently sucking the blood into a suction bottle
without any irrigation until the intracorporeal suturingwas completed and the haemosta-
sis confirmed
Notes Indications for myomectomy: symptomatic myomas
Authors not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation by computer-generated random
numbers
Allocation concealment (selection bias) Low risk Adequate
Incomplete outcome data (attrition bias)
All outcomes
High risk 8.3% (4/48) patients excluded because of
difficulties which led to them receiving the
treatment of the intervention arm and not
the control arm as randomised
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded
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Taylor 2005
Methods Two centre study
Allocation by sealed sequentially numbered opaque envelopes containing computer-
generated random numbers
Patients blinded but care providers not blinded
Power calculation: performed
No losses to follow up, and all patients were analysed in groups to which they were
assigned
Source of funding: not mentioned
Participants Setting: two university hospitals, London, UK
Inclusion criteria: symptomatic fibroids, uterine size at least 14weeks, and patient request
for myomectomy
Exclusion criteria: history of bleeding disorder, concurrent anti-coagulant therapy, hae-
moglobin less than 10.5g/dl at the time of surgery, pre-malignant endometrial histology
n = 28
Mean age: 39.5 years (SD 4.7) in control arm and 42.6 years (SD 6.7) in treatment arm
Ethnicity: not described
Number of fibroids: range 1-34
Interventions Treatment arm (n = 14): a number one polyglactin suture tied around the cervix to
occlude uterine artery and left there after surgery, plus a polythene tourniquet tied round
the infundibulopelvic ligament and removed after the operation
Control arm (n = 14): no treatment added to the normal myomectomy procedure
Type of operation: laparotomy
Outcomes Perioperative blood loss, need for blood transfusion, operative morbidity
Blood loss was assessed by weighing swabs and measuring blood collected by suction
Notes Indications for myomectomy: symptomatic uterine fibroids
Preoperative GnRH agonists prescribed to anaemic patients to increase preoperative
haemoglobin to more than 10.5g/dl
Authors contacted July 2015
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation by sealed sequentially-num-
bered opaque envelopes containing com-
puter-generated random numbers
Allocation concealment (selection bias) Low risk Adequate
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
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Taylor 2005 (Continued)
Other bias High risk Statistically significant difference in mean
age of the two groups
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients blinded but care providers not
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if outcome assessment blinded
Vercellino 2012
Methods Randomised controlled trial with 80 participants assigned to receive laparoscopic uterine
artery clipping and myomectomy, while 86 participants received laparoscopic myomec-
tomy only
Study conducted in three centres in Germany from January 2007 to December 2009
Power calculation performed
Participants Women between the ages of 18 and 50 years with the diagnosis symptomatic uterine
myomas and who had a combined diameter of
≥ 4cm were included into the study. Patients with severe accompanying medical prob-
lems, or psychiatric illnesses, which jeopardize participation, or undergoing treatment af-
fecting coagulation and/or hematopoiesis, and patients with suspected malignancy were
excluded
Ethnicity not described
Interventions All patients had laparoscopic myomectomy. The intervention group (Group A) had tem-
porary bilateral clipping of uterine arteries during myomectomy using Yasargil vascular
clips and the control group (Group B) received no additional treatment
Outcomes Outcomes measured were haemoglobin drop, duration of surgery, duration of hospital
stay, need for blood transfusion and complications
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generation by com-
puter-generated random numbers
Allocation concealment (selection bias) Low risk Patients allocated to study group tempo-
rary clipping of bilateral uterine arteries,
Group A) and control (Group B) by means
of sealed sequentially numbered brown
envelopes containing computer-generated
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Vercellino 2012 (Continued)
random numbers
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Randomisationwas done the day before the
surgery and patients were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No information
Wang 2007
Methods Single centre study
Participants were randomly allocated to either intervention or control group according
to a computer-generated sequence
Allocation using preprinted slips on sealed envelopes that had been prepared before the
started of the study with a computer-generated sequence
Information not given about blinding
Power calculation: performed
No losses to follow up and all patients were analysed in the group in which they were
allocated
Funding from the Medical Research Project, Chang Gung Memorial Hospital
Participants Setting: Chang Gung Memorial Hospital, Taiwan
Inclusion criteria: 60 women who had clinical diagnosis of symptomatic leiomyoma (at
least an intramural myoma that measured 5cm or more). Diagnosis of leiomyomata was
made by pelvic examination and ultrasound scanning in all patients
Exclusion criteria: patients with intrauterine lesions were excluded
n = 60
Age: mean age of women in the intervention group was 38.1 years (SD = 6.8) and of the
control group was 35.8 years (SD =6.1)
Ethnicity: not described
Mean fibroid size: 7.6 cm (SD = 2.2) in the treatment group and 7.5cm (SD = 1.9) in
the control group
Interventions Treatment arm (n = 30): oxytocin (10 u/mL/amp) in 1000 ml normal saline and run at
a rate of 120 mL/h. The administration of oxytocin was started after the anaesthesia was
completed. Intravenous oxytocin was stopped immediately after the end of the surgery
Control arm (n = 30): normal saline without oxytocin run at a rate of 120 mL/h
All patients had bowel preparation themorning of surgery and intravenous cephalosporin
prophylaxis was given just before surgery commenced
Type of operation: laparoscopy
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Wang 2007 (Continued)
Outcomes Number of fibroids removed, operation time, blood loss, hospital day (days), blood
transfusion, and complications
Notes Authors contacted
Fibroid size and number removed were similar in both groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly allocated to ei-
ther intervention or control group accord-
ing to a computer-generated sequence
Allocation concealment (selection bias) Low risk Adequate (allocation using preprinted slips
on sealed envelopes that had been prepared
before the start of the study with a com-
puter-generated sequence)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Normal saline without oxytocin was ad-
ministered to control group as placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information not given on blinding
Zhao 2011
Methods Single centre randomised controlled trial in which 35 participants received loop ligation
combined with vasopressin, 35 participants received vasopressin alone and 35 partici-
pants received neither loop ligation nor vasopressin
From January 2006 to January 2008
No power calculation performed
Participants Setting: Sheng Jing Hospital, China Medical University
Women with symptomatic myomas (diameter ≥ 6cm) needing surgical treatment
Ethnicity not reported
Age ranges from 22 to 49 years
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Zhao 2011 (Continued)
Interventions Group A: loop ligation of larger myoma pseudocapsules combined with vasopressin;
group B: vasopressin injection; and group C: neither loop ligation nor vasopressin in-
jection. Vasopressin injection consisted of 6U diluted with 20ml of normal saline and
injected into the myometrium and myoma. All patients had laparoscopic myomectomy.
Blood loss was measured by suction irrigator through subtracting the fluid used from
the total measured loss
Outcomes The outcomes measured were blood loss, operating time, postoperative stay, blood trans-
fusions, conversion to laparotomy
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It is stated that patients were randomly di-
vided into three groups by ‘simple random
method’.No details are given to explain the
simple random method
Allocation concealment (selection bias) Unclear risk The randomisation was concealed from the
surgeon until before the start of the opera-
tion. No further details are given
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The control group receive no treatment
rather than an identical placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
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Zullo 2004
Methods Single centre study
Allocation by envelopes containing computer-generated random numbers
Patients and care providers were blinded
Power calculation: performed
4 (6.7%) patients (2 in each arm ) did not receive the assigned intervention because of
concomitant disease (endometriosis)
Withdrawals were excluded from the analysis
Participants Setting: university hospital in Naples, Italy
Inclusion criteria: symptomatic fibroids
Exclusion criteria: liver disease, angina or ischaemic heart disease, chronic obstructive
pulmonary disease, dyslipidaemia, diabetes, acute or recent vascular thrombosis, malig-
nancy, intramural largest myoma less than 3 cm, or more than 5 cm, more than 2 my-
omas, calcification or hypoechoic leiomyoma, submucosal fibroids, cytologic evidence
of endometrial atypia, abnormal Pap smear, or positive urine pregnancy test
n = 60
Mean age: 28.2 years (SD 3.1) for treatment arm and 27.1 years (SD 2.9) for control
arm
Ethnicity: not described
Number of myomas: mean 1.3 (SD 0.4) in treatment arm and 1.2 (SD 0.3) in control
arm
Interventions Treatment arm (n = 30): 50 ml of bupivacaine cloridrate 0.25% + 0.5 ml of epinephrine
infiltrated into the serosa or myometrium overlying and just around the myoma before
incision
Control (n = 30): infiltration of normal saline
Type of operation: laparoscopy
Outcomes Perioperative blood loss, and operation time
Blood loss was estimated from the balance between the aspirated and the irrigated liquid
Notes Indications for myomectomy: history of infertility for more than 3 years, recurrent
abortions during first trimester, increased vaginal bleeding, pelvic pressure and pain,
urinary frequency, and constipation
Author not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation by envelopes containing com-
puter-generated random numbers
Allocation concealment (selection bias) Low risk Adequate
Incomplete outcome data (attrition bias)
All outcomes
High risk 4 (6.7%) patients (2 in each arm ) did not
receive the assigned intervention because of
concomitant disease (endometriosis)
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Zullo 2004 (Continued)
Selective reporting (reporting bias) Unclear risk We do not have access to the study protocol
Other bias Low risk No other sources of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients and care providers were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al-Shabibi 2010 No randomisation was performed
Alborzi 2009 No randomisation was performed
Alessandri 2006 The control group did not receive a placebo or not treatment. The trial compared two different techniques
Alessandri 2010 The control group did not receive a placebo or not treatment. The trial compared two different techniques
Chang 2009 No randomisation was performed
Chang 2011 No randomisation was performed
Chang 2012 No randomisation was performed
Fletcher 1996 The control group was not a placebo or no treatment group but rather another intervention
Frederick 2013 The control group was not a placebo or no treatment
Ginsburg 1993 The control group was not a placebo or no treatment group but rather another intervention
Kathiresan 2011 The control group was not a placebo or no treatment group but rather another intervention
Kimura 2002 The study compared blood loss when vertical and transverse incisions were performed during laparoscopic my-
omectomy. Thus there was no distinction between the treatment and control groups
Lee 2009 No randomisation was performed
Lin 2008 The control group was not a placebo or no treatment
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(Continued)
Liu 2004 No randomisation was performed
Morita 2004 No randomisation was performed
Mousa 2012 Control group received another intervention rather than a placebo or no treatment
Narin 2007 Control group received another intervention rather than a placebo or no treatment
Ngeh 2004 No randomisation was performed
Rossetti 1999 No randomisation was performed
Sapmaz 2003B The control group was not a placebo or no treatment group but rather another intervention
Sapmaz 2003C The control group was not a placebo or no treatment group, but rather another intervention
Wang 2011 The control group did not receive a placebo or not treatment. The trial compared two different techniques
Characteristics of ongoing studies [ordered by study ID]
Atashkhoei 2012
Trial name or title Effect of oxytocin infusion on reducing operative blood loss during abdominal myomectomy
Methods Randomised placebo controlled clinical trial
Participants Inclusion criteria: Including criteria: Women undergoing abdominal myomectomy; over 35 years of age
Excluding criteria: Patients candidate for hysteroscopic myomectomy; Patients with preoperative GnRH
agonist consumption; Patients with history of cardiopulmonary disease
Interventions Intervention 1: In the study group (n=40) oxytocin 30 u into 1000 ml normal saline will be infused during
myomectomy. Intervention 2: In the placebo group (n=40) normal saline alone 1000 ml will be infused
during myomectomy
Outcomes Primary Outcome(s):
The amount of bleeding. Timepoint: During myomectomy. Method of measurement: Count sponges and
the amount of blood collected in the suction device - according to ml
Secondary Outcome(s):
Hb and HcT values. Timepoint: Prior to operation and 24 h after operation. Method of measurement: Elyza
method-CBC - Hb(g/dl), HcT(%)
The amount of blood transfusion. Timepoint: Intra and postoperative.Method ofmeasurement:Observation,
Physical examination- Blood unit according to ml
Starting date November 2012
Contact information Dr Simin Atashkhoei, Al Zahra hospital, Artesh Jonoubi Ave, Tabriz, Iran
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Atashkhoei 2012 (Continued)
Notes
Behdad 2013
Trial name or title The effect of infusion of vitamin C during myomectomy on the blood loss during the procedure and post-
operative pain
Methods Randomised placebo controlled clinical trial
Participants Inclusion criteria: women with American Society of Anesthesia (ASA) physical status I or II who are candidate
for elective abdominal myomectomy, age 25-40 years old, BMI <35
Exclusion criteria: patients with mental impairment, chronic pain, BMI>35, a history of coagulopathy, psy-
chiatric disease, addiction were excluded
Interventions Intervention 1: Infusion of 3 gr vitamin C in 500 ml normal saline during the surgery
Intervention 2: Infusion of 500 ml normal saline without vitamin C during the surgery
Outcomes Primary Outcome(s): uterine bleeding. Timepoint: during the surgery. Method of measurement: ml blood
loss
Secondary Outcome(s): postoperative pain. Timepoint: 1, 6, 12 and 24 hours after the operation. Method
of measurement: VAS Score
Starting date October 2012
Contact information Dr Shekoufeh Behdad, Shahid Sadoughi Hospital Yazd, Iran
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Misoprostol versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 2 89 Mean Difference (IV, Fixed, 95% CI) -97.88 [-125.52, -
70.24]
1.1 Abdominal myomectomy 1 25 Mean Difference (IV, Fixed, 95% CI) -149.0 [-229.24, -
68.76]
1.2 Laparoscopic
myomectomy
1 64 Mean Difference (IV, Fixed, 95% CI) -91.0 [-120.44, -61.
56]
2 Need for blood transfusion 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Duration of surgery (min) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Abdominal myomectomy 1 25 Mean Difference (IV, Random, 95% CI) -9.5 [-15.90, -3.10]
3.2 Laparoscopic
myomectomy
1 64 Mean Difference (IV, Random, 95% CI) 9.0 [-1.63, 19.63]
4 Postoperative haemoglobin
(g/dl)
2 89 Mean Difference (IV, Fixed, 95% CI) 0.69 [0.37, 1.02]
5 Duration of hospital stay (days) 1 25 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.82, 0.82]
6 Postoperative haemoglobin drop
(g/dl)
1 67 Mean Difference (IV, Fixed, 95% CI) -0.60 [-0.78, -0.42]
7 Postoperative complications 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Postoperative fever 2 89 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.23, 3.88]
Comparison 2. Vasopressin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 3 128 Mean Difference (IV, Fixed, 95% CI) -199.97 [-223.83, -
176.12]
1.1 Abdominal myomectomy 1 20 Mean Difference (IV, Fixed, 95% CI) -450.00 [-507.49, -
392.51]
1.2 Laparoscopic
myomectomy
2 108 Mean Difference (IV, Fixed, 95% CI) -147.95 [-174.17, -
121.73]
2 Need for blood transfusion 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Abdominal myomectomy 1 20 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 1.24]
2.2 Laparoscopic
myomectomy
1 70 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.02, 1.60]
3 Duration of surgery (min) 2 108 Mean Difference (IV, Fixed, 95% CI) -27.72 [-35.82, -19.
61]
4 Duration of hospital stay (days) 2 108 Mean Difference (IV, Random, 95% CI) 0.11 [-0.69, 0.91]
5 Postoperative complications 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Adhesions to bowel and/or
omentum
1 38 Odds Ratio (M-H, Fixed, 95% CI) 2.02 [0.54, 7.49]
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5.2 Adnexal adhesions 1 38 Odds Ratio (M-H, Fixed, 95% CI) 1.87 [0.39, 8.93]
6 Pregnancy after myomectomy 1 38 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.18, 2.31]
7 Conversion of laparoscopy to
laparotomy
1 70 Odds Ratio (M-H, Fixed, 95% CI) 7.65 [0.38, 153.75]
Comparison 3. Bupivicaine plus epinephrine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 1 60 Mean Difference (IV, Fixed, 95% CI) -68.6 [-93.69, -43.
51]
2 Duration of surgery (min) 1 60 Mean Difference (IV, Fixed, 95% CI) -30.5 [-37.68, -23.
32]
Comparison 4. Peri-cervical tourniquet versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Blood loss - cervical
tourniquet (ml)
1 93 Mean Difference (IV, Fixed, 95% CI) -240.70 [-359.61, -
121.79]
1.2 Blood loss - cervical &
infundibulopelvic ligament
tourniquet
1 28 Mean Difference (IV, Fixed, 95% CI) -1870.0 [-2547.16, -
1192.84]
2 Need for blood transfusion 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Need for blood transfusion
- cervical tourniquet
1 93 Odds Ratio (M-H, Fixed, 95% CI) 0.22 [0.09, 0.55]
2.2 Need for blood transfusion
- cervical & infundibulopelvic
ligament tourniquet
1 28 Odds Ratio (M-H, Fixed, 95% CI) 0.02 [0.00, 0.23]
3 Duration of surgery (min) 1 28 Mean Difference (IV, Fixed, 95% CI) -4.0 [-29.28, 21.28]
4 Postoperative complications 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Postoperative fever 1 93 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.46, 2.59]
4.2 Postoperative anaemia 1 93 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.46, 2.59]
4.3 Urinary tract infection 1 93 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.13, 3.70]
4.4 Prolonged vaginal
bleeding
1 93 Odds Ratio (M-H, Fixed, 95% CI) 2.21 [0.09, 55.82]
4.5 Pelvic abscess 1 93 Odds Ratio (M-H, Fixed, 95% CI) 2.21 [0.09, 55.82]
4.6 Intestinal obstruction 1 93 Odds Ratio (M-H, Fixed, 95% CI) 2.21 [0.09, 55.82]
4.7 Bladder injury 1 93 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.01, 5.94]
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Comparison 5. Oxytocin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
2 Need for blood transfusion 2 154 Odds Ratio (M-H, Random, 95% CI) 0.54 [0.03, 8.51]
3 Duration of surgery (min) 2 154 Mean Difference (IV, Fixed, 95% CI) 3.50 [-1.88, 8.88]
4 Postoperative complications 1 60 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.76]
5 Duration of hospital stay (days) 1 60 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.19, -0.01]
Comparison 6. Chemical dissection with mesna versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Duration of surgery (min) 1 58 Mean Difference (IV, Fixed, 95% CI) -20.0 [-28.64, -11.
36]
2 Duration of hospital stay (days) 1 58 Mean Difference (IV, Fixed, 95% CI) -1.0 [-1.12, -0.88]
3 Postoperative haemoglobin
(g/dl)
1 58 Mean Difference (IV, Fixed, 95% CI) 0.5 [0.42, 0.58]
4 Postoperative haematocrit 1 58 Mean Difference (IV, Fixed, 95% CI) 1.90 [1.30, 2.50]
5 Postoperative complications 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Postoperative fever 1 58 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.22]
Comparison 7. Myoma morcellation versus standard technique of enucleation (no treatment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 1 48 Mean Difference (IV, Fixed, 95% CI) 65.40 [-36.47, 167.
27]
2 Duration of surgery (min) 1 48 Mean Difference (IV, Fixed, 95% CI) -25.30 [-44.23, -6.
37]
3 Duration of hospital stay (days) 1 48 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.18, 0.04]
68Interventions to reduce haemorrhage during myomectomy for fibroids (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 8. Intravenous injection of tranexamic acid versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 1 100 Mean Difference (IV, Fixed, 95% CI) -243.0 [-460.02, -
25.98]
2 Need for blood transfusion 1 100 Odds Ratio (M-H, Fixed, 95% CI) 1.71 [0.68, 4.30]
3 Duration of surgery (min) 1 100 Mean Difference (IV, Fixed, 95% CI) -11.0 [-21.09, -0.91]
4 Postoperative haemoglobin
(g/dl)
1 100 Mean Difference (IV, Fixed, 95% CI) 0.21 [-0.36, 0.78]
5 Postoperative haematocrit 1 100 Mean Difference (IV, Fixed, 95% CI) 1.0 [-0.43, 2.43]
Comparison 9. Gelatin-thrombin matrix versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 1 50 Mean Difference (IV, Fixed, 95% CI) -545.0 [-593.26, -
496.74]
2 Need for blood transfusion 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.01 [0.00, 0.10]
3 Postoperative vaginal blood loss
(ml)
1 50 Mean Difference (IV, Fixed, 95% CI) -225.0 [-254.46, -
195.54]
4 Duration of surgery (min) 1 50 Mean Difference (IV, Fixed, 95% CI) 5.0 [1.29, 8.71]
5 Postoperative haemoglobin drop
(g/dl)
1 50 Mean Difference (IV, Fixed, 95% CI) -2.3 [-2.66, -1.94]
6 Duration of hospital stay (days) 1 50 Mean Difference (IV, Fixed, 95% CI) -2.0 [-2.69, -1.31]
7 Postoperative fever 1 50 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.01, 8.25]
Comparison 10. Ascorbic acid versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 1 102 Mean Difference (IV, Fixed, 95% CI) -411.46 [-502.58, -
320.34]
2 Need for blood transfusion 1 102 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.11, 1.32]
3 Duration of surgery (min) 1 102 Mean Difference (IV, Fixed, 95% CI) -26.0 [-33.10, -18.
90]
4 Duration of hospital stay (days) 1 102 Mean Difference (IV, Fixed, 95% CI) -0.40 [-0.65, -0.15]
5 Posoperative haemoglobin drop
(g/dl)
1 102 Mean Difference (IV, Fixed, 95% CI) 0.14 [-0.22, 0.50]
6 Pospoerative hematocrit drop
(%)
1 102 Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.34, -0.06]
7 Posoperative complications 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Postoperative fever 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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7.2 Postoperative vomiting 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Postoperative constipation 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Severe pain 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 11. Dinoprostone versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 1 108 Mean Difference (IV, Fixed, 95% CI) -131.60 [-253.42, -
9.78]
2 Need for blood transfusion 1 108 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.04, 0.81]
3 Duration of surgery (min) 1 108 Mean Difference (IV, Fixed, 95% CI) -2.60 [-12.55, 7.35]
4 Duration of hospital stay (days) 1 108 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.22, 0.82]
5 Postoperative haemoglobin
(g/dl)
1 108 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.39, 0.59]
6 Postoperative haemoglobin drop
(g/dl)
1 108 Mean Difference (IV, Fixed, 95% CI) -0.5 [-0.88, -0.12]
7 Postoperative complications 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Postoperative fever 1 108 Odds Ratio (M-H, Fixed, 95% CI) 1.53 [0.25, 9.54]
Comparison 12. Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 1 70 Mean Difference (IV, Fixed, 95% CI) -305.01 [-354.83, -
255.19]
2 Need for blood transfusion 1 70 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.00, 1.47]
3 Duration of surgery (min) 1 70 Mean Difference (IV, Fixed, 95% CI) -32.76 [-40.81, -24.
71]
4 Duration of hospital stay (days) 1 70 Mean Difference (IV, Fixed, 95% CI) -1.46 [-1.85, -1.07]
Comparison 13. Temporary clipping of uterine artery versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Need for blood transfusion 1 166 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Duration of surgery (min) 1 166 Mean Difference (IV, Fixed, 95% CI) 40.0 [30.01, 49.99]
3 Postoperative haemoglobin drop
(g/dl)
1 166 Mean Difference (IV, Fixed, 95% CI) -0.25 [-0.61, 0.11]
4 Duration of hospital stay (days) 1 166 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.15, 0.15]
5 Postoperative complications 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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5.1 Postoperative bleeding 1 166 Odds Ratio (M-H, Fixed, 95% CI) 2.18 [0.19, 24.51]
5.2 Uterine hematoma 1 166 Odds Ratio (M-H, Fixed, 95% CI) 3.31 [0.34, 32.51]
5.3 Postoperative sepsis 1 166 Odds Ratio (M-H, Fixed, 95% CI) 3.26 [0.13, 81.29]
5.4 Bleeding from point of
trocar insertion
1 166 Odds Ratio (M-H, Fixed, 95% CI) 3.26 [0.13, 81.29]
5.5 Postoperative urinary tract
infection
1 166 Odds Ratio (M-H, Fixed, 95% CI) 3.26 [0.13, 81.29]
5.6 Trocar site hernia 1 166 Odds Ratio (M-H, Fixed, 95% CI) 3.26 [0.13, 81.29]
5.7 Sinus venous thrombosis 1 166 Odds Ratio (M-H, Fixed, 95% CI) 3.26 [0.13, 81.29]
5.8 Lung artery embolism 1 166 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.82]
5.9 Cardiac arrhythmia 1 166 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.82]
Comparison 14. Fibrin sealant patch versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss (ml) 1 70 Mean Difference (IV, Fixed, 95% CI) -26.5 [-44.47, -8.53]
2 Postoperative blood loss in
drainage bag
1 70 Mean Difference (IV, Fixed, 95% CI) -44.60 [-65.06, -24.
14]
3 Need for blood transfusion 1 70 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Duration of surgery (min) 1 70 Mean Difference (IV, Fixed, 95% CI) -0.40 [-4.47, 3.67]
5 Duration of hospital stay (days) 1 70 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.09, 0.09]
6 Conception after surgery 1 70 Odds Ratio (M-H, Fixed, 95% CI) 3.16 [0.76, 13.11]
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Analysis 1.1. Comparison 1 Misoprostol versus placebo, Outcome 1 Blood loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 1 Misoprostol versus placebo
Outcome: 1 Blood loss (ml)
Study or subgroup Misoprostol Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Abdominal myomectomy
Celik 2003 13 472 (77) 12 621 (121) 11.9 % -149.00 [ -229.24, -68.76 ]
Subtotal (95% CI) 13 12 11.9 % -149.00 [ -229.24, -68.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.64 (P = 0.00027)
2 Laparoscopic myomectomy
Kalogiannidis 2011 30 126 (44) 34 217 (74) 88.1 % -91.00 [ -120.44, -61.56 ]
Subtotal (95% CI) 30 34 88.1 % -91.00 [ -120.44, -61.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.06 (P < 0.00001)
Total (95% CI) 43 46 100.0 % -97.88 [ -125.52, -70.24 ]
Heterogeneity: Chi2 = 1.77, df = 1 (P = 0.18); I2 =43%
Test for overall effect: Z = 6.94 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.77, df = 1 (P = 0.18), I2 =43%
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Analysis 1.2. Comparison 1 Misoprostol versus placebo, Outcome 2 Need for blood transfusion.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 1 Misoprostol versus placebo
Outcome: 2 Need for blood transfusion
Study or subgroup Misoprostol Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Celik 2003 2/13 4/12 0.36 [ 0.05, 2.50 ]
Kalogiannidis 2011 0/30 0/34 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 2 (Misoprostol), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Misoprostol versus placebo, Outcome 3 Duration of surgery (min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 1 Misoprostol versus placebo
Outcome: 3 Duration of surgery (min)
Study or subgroup Misoprostol Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Abdominal myomectomy
Celik 2003 13 48.5 (7.4) 12 58 (8.8) 100.0 % -9.50 [ -15.90, -3.10 ]
Subtotal (95% CI) 13 12 100.0 % -9.50 [ -15.90, -3.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.91 (P = 0.0036)
2 Laparoscopic myomectomy
Kalogiannidis 2011 30 86 (23) 34 77 (20) 100.0 % 9.00 [ -1.63, 19.63 ]
Subtotal (95% CI) 30 34 100.0 % 9.00 [ -1.63, 19.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Chi2 = 8.54, df = 1 (P = 0.00), I2 =88%
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Analysis 1.4. Comparison 1 Misoprostol versus placebo, Outcome 4 Postoperative haemoglobin (g/dl).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 1 Misoprostol versus placebo
Outcome: 4 Postoperative haemoglobin (g/dl)
Study or subgroup Misoprostol Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Celik 2003 13 9.7 (0.7) 12 8.9 (0.5) 46.5 % 0.80 [ 0.33, 1.27 ]
Kalogiannidis 2011 30 11.6 (1.1) 34 11 (0.6) 53.5 % 0.60 [ 0.16, 1.04 ]
Total (95% CI) 43 46 100.0 % 0.69 [ 0.37, 1.02 ]
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 4.20 (P = 0.000027)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Misoprostol versus placebo, Outcome 5 Duration of hospital stay (days).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 1 Misoprostol versus placebo
Outcome: 5 Duration of hospital stay (days)
Study or subgroup Misoprostol Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Celik 2003 13 4.2 (0.4) 12 4.2 (1.4) 100.0 % 0.0 [ -0.82, 0.82 ]
Total (95% CI) 13 12 100.0 % 0.0 [ -0.82, 0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Misoprostol versus placebo, Outcome 6 Postoperative haemoglobin drop (g/dl).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 1 Misoprostol versus placebo
Outcome: 6 Postoperative haemoglobin drop (g/dl)
Study or subgroup Misoprostol Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kalogiannidis 2011 33 1 (0.33) 34 1.6 (0.43) 100.0 % -0.60 [ -0.78, -0.42 ]
Total (95% CI) 33 34 100.0 % -0.60 [ -0.78, -0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.42 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Misoprostol versus placebo, Outcome 7 Postoperative complications.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 1 Misoprostol versus placebo
Outcome: 7 Postoperative complications
Study or subgroup Misoprostol Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Postoperative fever
Celik 2003 5/13 4/12 64.9 % 1.25 [ 0.24, 6.44 ]
Kalogiannidis 2011 0/30 1/34 35.1 % 0.37 [ 0.01, 9.33 ]
Subtotal (95% CI) 43 46 100.0 % 0.94 [ 0.23, 3.88 ]
Total events: 5 (Misoprostol), 5 (Placebo)
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Vasopressin versus placebo, Outcome 1 Blood loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 2 Vasopressin versus placebo
Outcome: 1 Blood loss (ml)
Study or subgroup Vasopressin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Abdominal myomectomy
Frederick 1994 10 225 (59.38) 10 675 (71.25) 17.2 % -450.00 [ -507.49, -392.51 ]
Subtotal (95% CI) 10 10 17.2 % -450.00 [ -507.49, -392.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 15.34 (P < 0.00001)
2 Laparoscopic myomectomy
Assaf 1999 21 220.6 (50) 17 370.2 (40) 69.5 % -149.60 [ -178.22, -120.98 ]
Zhao 2011 35 224.35 (131.17) 35 363.68 (147.83) 13.3 % -139.33 [ -204.81, -73.85 ]
Subtotal (95% CI) 56 52 82.8 % -147.95 [ -174.17, -121.73 ]
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 11.06 (P < 0.00001)
Total (95% CI) 66 62 100.0 % -199.97 [ -223.83, -176.12 ]
Heterogeneity: Chi2 = 87.87, df = 2 (P<0.00001); I2 =98%
Test for overall effect: Z = 16.43 (P < 0.00001)
Test for subgroup differences: Chi2 = 87.79, df = 1 (P = 0.00), I2 =99%
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Analysis 2.2. Comparison 2 Vasopressin versus placebo, Outcome 2 Need for blood transfusion.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 2 Vasopressin versus placebo
Outcome: 2 Need for blood transfusion
Study or subgroup Favours vasopressin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Abdominal myomectomy
Frederick 1994 1/10 5/10 100.0 % 0.11 [ 0.01, 1.24 ]
Subtotal (95% CI) 10 10 100.0 % 0.11 [ 0.01, 1.24 ]
Total events: 1 (Favours vasopressin), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
2 Laparoscopic myomectomy
Zhao 2011 1/35 5/35 100.0 % 0.18 [ 0.02, 1.60 ]
Subtotal (95% CI) 35 35 100.0 % 0.18 [ 0.02, 1.60 ]
Total events: 1 (Favours vasopressin), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
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Analysis 2.3. Comparison 2 Vasopressin versus placebo, Outcome 3 Duration of surgery (min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 2 Vasopressin versus placebo
Outcome: 3 Duration of surgery (min)
Study or subgroup Vasopressin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Assaf 1999 21 97.8 (40) 17 126.3 (60) 5.9 % -28.50 [ -61.76, 4.76 ]
Zhao 2011 35 76.51 (17.14) 35 104.18 (18.51) 94.1 % -27.67 [ -36.03, -19.31 ]
Total (95% CI) 56 52 100.0 % -27.72 [ -35.82, -19.61 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 6.70 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Vasopressin versus placebo, Outcome 4 Duration of hospital stay (days).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 2 Vasopressin versus placebo
Outcome: 4 Duration of hospital stay (days)
Study or subgroup Vasopressin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Assaf 1999 21 1.79 (1.16) 17 1.24 (0.89) 46.0 % 0.55 [ -0.10, 1.20 ]
Zhao 2011 35 4.32 (0.91) 35 4.59 (1.08) 54.0 % -0.27 [ -0.74, 0.20 ]
Total (95% CI) 56 52 100.0 % 0.11 [ -0.69, 0.91 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 4.01, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Vasopressin versus placebo, Outcome 5 Postoperative complications.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 2 Vasopressin versus placebo
Outcome: 5 Postoperative complications
Study or subgroup Vsaopressin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adhesions to bowel and/or omentum
Assaf 1999 11/21 6/17 100.0 % 2.02 [ 0.54, 7.49 ]
Subtotal (95% CI) 21 17 100.0 % 2.02 [ 0.54, 7.49 ]
Total events: 11 (Vsaopressin), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 Adnexal adhesions
Assaf 1999 6/21 3/17 100.0 % 1.87 [ 0.39, 8.93 ]
Subtotal (95% CI) 21 17 100.0 % 1.87 [ 0.39, 8.93 ]
Total events: 6 (Vsaopressin), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
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Analysis 2.6. Comparison 2 Vasopressin versus placebo, Outcome 6 Pregnancy after myomectomy.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 2 Vasopressin versus placebo
Outcome: 6 Pregnancy after myomectomy
Study or subgroup Favours placebo Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Assaf 1999 10/21 10/17 100.0 % 0.64 [ 0.18, 2.31 ]
Total (95% CI) 21 17 100.0 % 0.64 [ 0.18, 2.31 ]
Total events: 10 (Favours placebo), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Vasopressin versus placebo, Outcome 7 Conversion of laparoscopy to
laparotomy.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 2 Vasopressin versus placebo
Outcome: 7 Conversion of laparoscopy to laparotomy
Study or subgroup Vasopressin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zhao 2011 3/35 0/35 100.0 % 7.65 [ 0.38, 153.75 ]
Total (95% CI) 35 35 100.0 % 7.65 [ 0.38, 153.75 ]
Total events: 3 (Vasopressin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Bupivicaine plus epinephrine versus placebo, Outcome 1 Blood loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 3 Bupivicaine plus epinephrine versus placebo
Outcome: 1 Blood loss (ml)
Study or subgroup Bupivacaine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zullo 2004 30 143.9 (48.1) 30 212.5 (51) 100.0 % -68.60 [ -93.69, -43.51 ]
Total (95% CI) 30 30 100.0 % -68.60 [ -93.69, -43.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.36 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Bupivicaine plus epinephrine versus placebo, Outcome 2 Duration of surgery
(min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 3 Bupivicaine plus epinephrine versus placebo
Outcome: 2 Duration of surgery (min)
Study or subgroup Bupivacaine Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zullo 2004 30 78.7 (13.1) 30 109.2 (15.2) 100.0 % -30.50 [ -37.68, -23.32 ]
Total (95% CI) 30 30 100.0 % -30.50 [ -37.68, -23.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.33 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Peri-cervical tourniquet versus no treatment, Outcome 1 Blood loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 4 Peri-cervical tourniquet versus no treatment
Outcome: 1 Blood loss (ml)
Study or subgroup Tourniquet No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Blood loss - cervical tourniquet (ml)
Ikechebelu 2010 54 515.7 (292.8) 39 756.4 (285.7) 100.0 % -240.70 [ -359.61, -121.79 ]
Subtotal (95% CI) 54 39 100.0 % -240.70 [ -359.61, -121.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.97 (P = 0.000073)
2 Blood loss - cervical % infundibulopelvic ligament tourniquet
Taylor 2005 14 489 (362) 14 2359 (1241) 100.0 % -1870.00 [ -2547.16, -1192.84 ]
Subtotal (95% CI) 14 14 100.0 % -1870.00 [ -2547.16, -1192.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.41 (P < 0.00001)
Test for subgroup differences: Chi2 = 21.57, df = 1 (P = 0.00), I2 =95%
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Analysis 4.2. Comparison 4 Peri-cervical tourniquet versus no treatment, Outcome 2 Need for blood
transfusion.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 4 Peri-cervical tourniquet versus no treatment
Outcome: 2 Need for blood transfusion
Study or subgroup Tourniquet No treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Need for blood transfusion - cervical tourniquet
Ikechebelu 2010 11/54 21/39 100.0 % 0.22 [ 0.09, 0.55 ]
Subtotal (95% CI) 54 39 100.0 % 0.22 [ 0.09, 0.55 ]
Total events: 11 (Tourniquet), 21 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 3.25 (P = 0.0011)
2 Need for blood transfusion - cervical % infundibulopelvic ligament tourniquet
Taylor 2005 1/14 11/14 100.0 % 0.02 [ 0.00, 0.23 ]
Subtotal (95% CI) 14 14 100.0 % 0.02 [ 0.00, 0.23 ]
Total events: 1 (Tourniquet), 11 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 3.15 (P = 0.0016)
Test for subgroup differences: Chi2 = 3.20, df = 1 (P = 0.07), I2 =69%
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Analysis 4.3. Comparison 4 Peri-cervical tourniquet versus no treatment, Outcome 3 Duration of surgery
(min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 4 Peri-cervical tourniquet versus no treatment
Outcome: 3 Duration of surgery (min)
Study or subgroup Tourniquet No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Taylor 2005 14 114 (27) 14 118 (40) 100.0 % -4.00 [ -29.28, 21.28 ]
Total (95% CI) 14 14 100.0 % -4.00 [ -29.28, 21.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Peri-cervical tourniquet versus no treatment, Outcome 4 Postoperative
complications.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 4 Peri-cervical tourniquet versus no treatment
Outcome: 4 Postoperative complications
Study or subgroup
Peri-
cervical
tourniquet No treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Postoperative fever
Ikechebelu 2010 19/54 13/39 100.0 % 1.09 [ 0.46, 2.59 ]
Subtotal (95% CI) 54 39 100.0 % 1.09 [ 0.46, 2.59 ]
Total events: 19 (Peri-cervical tourniquet), 13 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
2 Postoperative anaemia
Ikechebelu 2010 19/54 13/39 100.0 % 1.09 [ 0.46, 2.59 ]
Subtotal (95% CI) 54 39 100.0 % 1.09 [ 0.46, 2.59 ]
Total events: 19 (Peri-cervical tourniquet), 13 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
3 Urinary tract infection
Ikechebelu 2010 3/54 3/39 100.0 % 0.71 [ 0.13, 3.70 ]
Subtotal (95% CI) 54 39 100.0 % 0.71 [ 0.13, 3.70 ]
Total events: 3 (Peri-cervical tourniquet), 3 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
4 Prolonged vaginal bleeding
Ikechebelu 2010 1/54 0/39 100.0 % 2.21 [ 0.09, 55.82 ]
Subtotal (95% CI) 54 39 100.0 % 2.21 [ 0.09, 55.82 ]
Total events: 1 (Peri-cervical tourniquet), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
5 Pelvic abscess
Ikechebelu 2010 1/54 0/39 100.0 % 2.21 [ 0.09, 55.82 ]
Subtotal (95% CI) 54 39 100.0 % 2.21 [ 0.09, 55.82 ]
Total events: 1 (Peri-cervical tourniquet), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
6 Intestinal obstruction
Ikechebelu 2010 1/54 0/39 100.0 % 2.21 [ 0.09, 55.82 ]
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(. . . Continued)
Study or subgroup
Peri-
cervical
tourniquet No treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 54 39 100.0 % 2.21 [ 0.09, 55.82 ]
Total events: 1 (Peri-cervical tourniquet), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
7 Bladder injury
Ikechebelu 2010 0/54 1/39 100.0 % 0.24 [ 0.01, 5.94 ]
Subtotal (95% CI) 54 39 100.0 % 0.24 [ 0.01, 5.94 ]
Total events: 0 (Peri-cervical tourniquet), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
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Analysis 5.1. Comparison 5 Oxytocin versus placebo, Outcome 1 Blood loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 5 Oxytocin versus placebo
Outcome: 1 Blood loss (ml)
Study or subgroup Oxytocin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Agostini 2005 47 508 (558) 47 451 (336) 57.00 [ -129.22, 243.22 ]
Wang 2007 30 269.5 (225.8) 30 445 (268.6) -175.50 [ -301.07, -49.93 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 5.2. Comparison 5 Oxytocin versus placebo, Outcome 2 Need for blood transfusion.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 5 Oxytocin versus placebo
Outcome: 2 Need for blood transfusion
Study or subgroup Oxytocin Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Agostini 2005 26/47 18/47 53.2 % 1.99 [ 0.88, 4.54 ]
Wang 2007 2/30 11/30 46.8 % 0.12 [ 0.02, 0.62 ]
Total (95% CI) 77 77 100.0 % 0.54 [ 0.03, 8.51 ]
Total events: 28 (Oxytocin), 29 (Placebo)
Heterogeneity: Tau2 = 3.54; Chi2 = 9.27, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours oxytocin Favours placebo
Analysis 5.3. Comparison 5 Oxytocin versus placebo, Outcome 3 Duration of surgery (min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 5 Oxytocin versus placebo
Outcome: 3 Duration of surgery (min)
Study or subgroup Oxytocin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Agostini 2005 47 90 (12) 47 86 (15) 95.8 % 4.00 [ -1.49, 9.49 ]
Wang 2007 30 119.2 (55.3) 30 127.2 (48.7) 4.2 % -8.00 [ -34.37, 18.37 ]
Total (95% CI) 77 77 100.0 % 3.50 [ -1.88, 8.88 ]
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Oxytocin versus placebo, Outcome 4 Postoperative complications.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 5 Oxytocin versus placebo
Outcome: 4 Postoperative complications
Study or subgroup Oxytocin Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wang 2007 1/30 1/30 100.0 % 1.00 [ 0.06, 16.76 ]
Total (95% CI) 30 30 100.0 % 1.00 [ 0.06, 16.76 ]
Total events: 1 (Oxytocin), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours oxytocin Favours placebo
89Interventions to reduce haemorrhage during myomectomy for fibroids (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.5. Comparison 5 Oxytocin versus placebo, Outcome 5 Duration of hospital stay (days).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 5 Oxytocin versus placebo
Outcome: 5 Duration of hospital stay (days)
Study or subgroup Oxytocin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wang 2007 30 2.7 (0.7) 30 3.3 (1.5) 100.0 % -0.60 [ -1.19, -0.01 ]
Total (95% CI) 30 30 100.0 % -0.60 [ -1.19, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.047)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Chemical dissection with mesna versus placebo, Outcome 1 Duration of
surgery (min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 6 Chemical dissection with mesna versus placebo
Outcome: 1 Duration of surgery (min)
Study or subgroup Mesna Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Benassi 2000 29 70 (14.25) 29 90 (19) 100.0 % -20.00 [ -28.64, -11.36 ]
Total (95% CI) 29 29 100.0 % -20.00 [ -28.64, -11.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.53 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Chemical dissection with mesna versus placebo, Outcome 2 Duration of
hospital stay (days).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 6 Chemical dissection with mesna versus placebo
Outcome: 2 Duration of hospital stay (days)
Study or subgroup Mesna Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Benassi 2000 29 2 (0.24) 29 3 (0.24) 100.0 % -1.00 [ -1.12, -0.88 ]
Total (95% CI) 29 29 100.0 % -1.00 [ -1.12, -0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 15.87 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Chemical dissection with mesna versus placebo, Outcome 3 Postoperative
haemoglobin (g/dl).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 6 Chemical dissection with mesna versus placebo
Outcome: 3 Postoperative haemoglobin (g/dl)
Study or subgroup Mesna Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Benassi 2000 29 10.3 (0.17) 29 9.8 (0.14) 100.0 % 0.50 [ 0.42, 0.58 ]
Total (95% CI) 29 29 100.0 % 0.50 [ 0.42, 0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.23 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Chemical dissection with mesna versus placebo, Outcome 4 Postoperative
haematocrit.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 6 Chemical dissection with mesna versus placebo
Outcome: 4 Postoperative haematocrit
Study or subgroup Mesna Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Benassi 2000 29 34.4 (1.26) 29 32.5 (1.07) 100.0 % 1.90 [ 1.30, 2.50 ]
Total (95% CI) 29 29 100.0 % 1.90 [ 1.30, 2.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.19 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 Chemical dissection with mesna versus placebo, Outcome 5 Postoperative
complications.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 6 Chemical dissection with mesna versus placebo
Outcome: 5 Postoperative complications
Study or subgroup Mesna Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Postoperative fever
Benassi 2000 1/29 6/29 100.0 % 0.14 [ 0.02, 1.22 ]
Subtotal (95% CI) 29 29 100.0 % 0.14 [ 0.02, 1.22 ]
Total events: 1 (Mesna), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
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Analysis 7.1. Comparison 7 Myoma morcellation versus standard technique of enucleation (no treatment),
Outcome 1 Blood loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 7 Myoma morcellation versus standard technique of enucleation (no treatment)
Outcome: 1 Blood loss (ml)
Study or subgroup Morcellation No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sinha 2005 24 283.9 (229.3) 24 218.5 (110.7) 100.0 % 65.40 [ -36.47, 167.27 ]
Total (95% CI) 24 24 100.0 % 65.40 [ -36.47, 167.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Myoma morcellation versus standard technique of enucleation (no treatment),
Outcome 2 Duration of surgery (min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 7 Myoma morcellation versus standard technique of enucleation (no treatment)
Outcome: 2 Duration of surgery (min)
Study or subgroup Myoma morcellation No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sinha 2005 24 97.7 (27.06) 24 123 (38.8) 100.0 % -25.30 [ -44.23, -6.37 ]
Total (95% CI) 24 24 100.0 % -25.30 [ -44.23, -6.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0088)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Myoma morcellation versus standard technique of enucleation (no treatment),
Outcome 3 Duration of hospital stay (days).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 7 Myoma morcellation versus standard technique of enucleation (no treatment)
Outcome: 3 Duration of hospital stay (days)
Study or subgroup Myoma morcellation No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sinha 2005 24 1.58 (0.23) 24 1.65 (0.15) 100.0 % -0.07 [ -0.18, 0.04 ]
Total (95% CI) 24 24 100.0 % -0.07 [ -0.18, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Intravenous injection of tranexamic acid versus placebo, Outcome 1 Blood loss
(ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 8 Intravenous injection of tranexamic acid versus placebo
Outcome: 1 Blood loss (ml)
Study or subgroup Tranexamic Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Caglar 2008 50 804 (482) 50 1047 (617) 100.0 % -243.00 [ -460.02, -25.98 ]
Total (95% CI) 50 50 100.0 % -243.00 [ -460.02, -25.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Intravenous injection of tranexamic acid versus placebo, Outcome 2 Need for
blood transfusion.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 8 Intravenous injection of tranexamic acid versus placebo
Outcome: 2 Need for blood transfusion
Study or subgroup Tranexamic Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Caglar 2008 15/50 10/50 100.0 % 1.71 [ 0.68, 4.30 ]
Total (95% CI) 50 50 100.0 % 1.71 [ 0.68, 4.30 ]
Total events: 15 (Tranexamic), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Intravenous injection of tranexamic acid versus placebo, Outcome 3 Duration
of surgery (min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 8 Intravenous injection of tranexamic acid versus placebo
Outcome: 3 Duration of surgery (min)
Study or subgroup Tranexamic Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Caglar 2008 50 73 (22) 50 84 (29) 100.0 % -11.00 [ -21.09, -0.91 ]
Total (95% CI) 50 50 100.0 % -11.00 [ -21.09, -0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.033)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 Intravenous injection of tranexamic acid versus placebo, Outcome 4
Postoperative haemoglobin (g/dl).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 8 Intravenous injection of tranexamic acid versus placebo
Outcome: 4 Postoperative haemoglobin (g/dl)
Study or subgroup Tranexamic Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Caglar 2008 50 9.97 (1.5) 50 9.76 (1.4) 100.0 % 0.21 [ -0.36, 0.78 ]
Total (95% CI) 50 50 100.0 % 0.21 [ -0.36, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 Intravenous injection of tranexamic acid versus placebo, Outcome 5
Postoperative haematocrit.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 8 Intravenous injection of tranexamic acid versus placebo
Outcome: 5 Postoperative haematocrit
Study or subgroup Tranexamic Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Caglar 2008 50 31.7 (3.9) 50 30.7 (3.4) 100.0 % 1.00 [ -0.43, 2.43 ]
Total (95% CI) 50 50 100.0 % 1.00 [ -0.43, 2.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 1 Blood
loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 9 Gelatin-thrombin matrix versus placebo or no treatment
Outcome: 1 Blood loss (ml)
Study or subgroup Gelatin-thrombin No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Raga 2009 25 80 (25.2) 25 625 (120.5) 100.0 % -545.00 [ -593.26, -496.74 ]
Total (95% CI) 25 25 100.0 % -545.00 [ -593.26, -496.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 22.14 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 2 Need for
blood transfusion.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 9 Gelatin-thrombin matrix versus placebo or no treatment
Outcome: 2 Need for blood transfusion
Study or subgroup Gelatin-thrombin No treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Raga 2009 0/25 20/25 100.0 % 0.01 [ 0.00, 0.10 ]
Total (95% CI) 25 25 100.0 % 0.01 [ 0.00, 0.10 ]
Total events: 0 (Gelatin-thrombin), 20 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 3.48 (P = 0.00050)
Test for subgroup differences: Not applicable
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Analysis 9.3. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 3
Postoperative vaginal blood loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 9 Gelatin-thrombin matrix versus placebo or no treatment
Outcome: 3 Postoperative vaginal blood loss (ml)
Study or subgroup Gelatin-thrombin No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Raga 2009 25 25 (5) 25 250 (75) 100.0 % -225.00 [ -254.46, -195.54 ]
Total (95% CI) 25 25 100.0 % -225.00 [ -254.46, -195.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 14.97 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.4. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 4 Duration
of surgery (min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 9 Gelatin-thrombin matrix versus placebo or no treatment
Outcome: 4 Duration of surgery (min)
Study or subgroup Gelatin-thrombin No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Raga 2009 25 65 (5.2) 25 60 (7.9) 100.0 % 5.00 [ 1.29, 8.71 ]
Total (95% CI) 25 25 100.0 % 5.00 [ 1.29, 8.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0082)
Test for subgroup differences: Not applicable
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Analysis 9.5. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 5
Postoperative haemoglobin drop (g/dl).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 9 Gelatin-thrombin matrix versus placebo or no treatment
Outcome: 5 Postoperative haemoglobin drop (g/dl)
Study or subgroup Gelatin-thrombin No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Raga 2009 25 0.5 (0.2) 25 2.8 (0.9) 100.0 % -2.30 [ -2.66, -1.94 ]
Total (95% CI) 25 25 100.0 % -2.30 [ -2.66, -1.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.6. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 6 Duration
of hospital stay (days).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 9 Gelatin-thrombin matrix versus placebo or no treatment
Outcome: 6 Duration of hospital stay (days)
Study or subgroup Gelatin-thrombin No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Raga 2009 25 2.5 (1.2) 25 4.5 (1.3) 100.0 % -2.00 [ -2.69, -1.31 ]
Total (95% CI) 25 25 100.0 % -2.00 [ -2.69, -1.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.65 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.7. Comparison 9 Gelatin-thrombin matrix versus placebo or no treatment, Outcome 7
Postoperative fever.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 9 Gelatin-thrombin matrix versus placebo or no treatment
Outcome: 7 Postoperative fever
Study or subgroup Gelatin-thrombin No treatment Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Raga 2009 0/25 1/25 100.0 % 0.32 [ 0.01, 8.25 ]
Total (95% CI) 25 25 100.0 % 0.32 [ 0.01, 8.25 ]
Total events: 0 (Gelatin-thrombin), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 1 Blood loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 10 Ascorbic acid versus placebo or no treatment
Outcome: 1 Blood loss (ml)
Study or subgroup Ascorbic acid No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pourmatroud 2012 52 521.44 (199.24) 50 932.9 (264.38) 100.0 % -411.46 [ -502.58, -320.34 ]
Total (95% CI) 52 50 100.0 % -411.46 [ -502.58, -320.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.85 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 2 Need for blood
transfusion.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 10 Ascorbic acid versus placebo or no treatment
Outcome: 2 Need for blood transfusion
Study or subgroup Ascorbic acid No treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pourmatroud 2012 4/52 9/50 100.0 % 0.38 [ 0.11, 1.32 ]
Total (95% CI) 52 50 100.0 % 0.38 [ 0.11, 1.32 ]
Total events: 4 (Ascorbic acid), 9 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 3 Duration of
surgery (min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 10 Ascorbic acid versus placebo or no treatment
Outcome: 3 Duration of surgery (min)
Study or subgroup Ascorbic acid No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pourmatroud 2012 52 42 (13.9) 50 68 (21.7) 100.0 % -26.00 [ -33.10, -18.90 ]
Total (95% CI) 52 50 100.0 % -26.00 [ -33.10, -18.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.17 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.4. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 4 Duration of
hospital stay (days).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 10 Ascorbic acid versus placebo or no treatment
Outcome: 4 Duration of hospital stay (days)
Study or subgroup Ascorbic acid No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pourmatroud 2012 52 2.7 (0.69) 50 3.1 (0.59) 100.0 % -0.40 [ -0.65, -0.15 ]
Total (95% CI) 52 50 100.0 % -0.40 [ -0.65, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.15 (P = 0.0016)
Test for subgroup differences: Not applicable
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Analysis 10.5. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 5 Posoperative
haemoglobin drop (g/dl).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 10 Ascorbic acid versus placebo or no treatment
Outcome: 5 Posoperative haemoglobin drop (g/dl)
Study or subgroup Ascorbic acid No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pourmatroud 2012 52 0.91 (0.83) 50 0.77 (1) 100.0 % 0.14 [ -0.22, 0.50 ]
Total (95% CI) 52 50 100.0 % 0.14 [ -0.22, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 10.6. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 6 Pospoerative
hematocrit drop (%).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 10 Ascorbic acid versus placebo or no treatment
Outcome: 6 Pospoerative hematocrit drop (%)
Study or subgroup Ascorbic acid No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pourmatroud 2012 52 -2.3 (1.6) 50 -1.6 (1.7) 100.0 % -0.70 [ -1.34, -0.06 ]
Total (95% CI) 52 50 100.0 % -0.70 [ -1.34, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Not applicable
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Analysis 10.7. Comparison 10 Ascorbic acid versus placebo or no treatment, Outcome 7 Posoperative
complications.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 10 Ascorbic acid versus placebo or no treatment
Outcome: 7 Posoperative complications
Study or subgroup Favours ascorbic acid No treatment Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Postoperative fever
Pourmatroud 2012 9/52 5/50 1.88 [ 0.58, 6.07 ]
2 Postoperative vomiting
Pourmatroud 2012 2/52 1/50 1.96 [ 0.17, 22.32 ]
3 Postoperative constipation
Pourmatroud 2012 0/52 1/50 0.31 [ 0.01, 7.90 ]
4 Severe pain
Pourmatroud 2012 4/52 2/50 2.00 [ 0.35, 11.44 ]
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Analysis 11.1. Comparison 11 Dinoprostone versus placebo, Outcome 1 Blood loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 11 Dinoprostone versus placebo
Outcome: 1 Blood loss (ml)
Study or subgroup Dinoprostone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shokeir 2013 54 354.1 (279.4) 54 485.7 (361.3) 100.0 % -131.60 [ -253.42, -9.78 ]
Total (95% CI) 54 54 100.0 % -131.60 [ -253.42, -9.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Dinoprostone versus placebo, Outcome 2 Need for blood transfusion.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 11 Dinoprostone versus placebo
Outcome: 2 Need for blood transfusion
Study or subgroup Dinoprostone Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shokeir 2013 2/54 10/54 100.0 % 0.17 [ 0.04, 0.81 ]
Total (95% CI) 54 54 100.0 % 0.17 [ 0.04, 0.81 ]
Total events: 2 (Dinoprostone), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Dinoprostone versus placebo, Outcome 3 Duration of surgery (min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 11 Dinoprostone versus placebo
Outcome: 3 Duration of surgery (min)
Study or subgroup Dinoprostone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shokeir 2013 54 82.8 (31.5) 54 85.4 (20) 100.0 % -2.60 [ -12.55, 7.35 ]
Total (95% CI) 54 54 100.0 % -2.60 [ -12.55, 7.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 11.4. Comparison 11 Dinoprostone versus placebo, Outcome 4 Duration of hospital stay (days).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 11 Dinoprostone versus placebo
Outcome: 4 Duration of hospital stay (days)
Study or subgroup Dinoprostone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shokeir 2013 54 3.3 (0.7) 54 3 (1.8) 100.0 % 0.30 [ -0.22, 0.82 ]
Total (95% CI) 54 54 100.0 % 0.30 [ -0.22, 0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 11.5. Comparison 11 Dinoprostone versus placebo, Outcome 5 Postoperative haemoglobin (g/dl).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 11 Dinoprostone versus placebo
Outcome: 5 Postoperative haemoglobin (g/dl)
Study or subgroup Dinoprostone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shokeir 2013 54 9.5 (1.2) 54 9.4 (1.4) 100.0 % 0.10 [ -0.39, 0.59 ]
Total (95% CI) 54 54 100.0 % 0.10 [ -0.39, 0.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 11.6. Comparison 11 Dinoprostone versus placebo, Outcome 6 Postoperative haemoglobin drop
(g/dl).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 11 Dinoprostone versus placebo
Outcome: 6 Postoperative haemoglobin drop (g/dl)
Study or subgroup Dinoprostone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shokeir 2013 54 1.4 (0.2) 54 1.9 (1.4) 100.0 % -0.50 [ -0.88, -0.12 ]
Total (95% CI) 54 54 100.0 % -0.50 [ -0.88, -0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0094)
Test for subgroup differences: Not applicable
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Analysis 11.7. Comparison 11 Dinoprostone versus placebo, Outcome 7 Postoperative complications.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 11 Dinoprostone versus placebo
Outcome: 7 Postoperative complications
Study or subgroup Dinoprostone Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Postoperative fever
Shokeir 2013 3/54 2/54 100.0 % 1.53 [ 0.25, 9.54 ]
Subtotal (95% CI) 54 54 100.0 % 1.53 [ 0.25, 9.54 ]
Total events: 3 (Dinoprostone), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment,
Outcome 1 Blood loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment
Outcome: 1 Blood loss (ml)
Study or subgroup
Ligation
plus
vasopressin No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zhao 2011 35 58.67 (27.53) 35 363.68 (147.83) 100.0 % -305.01 [ -354.83, -255.19 ]
Total (95% CI) 35 35 100.0 % -305.01 [ -354.83, -255.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.00 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment,
Outcome 2 Need for blood transfusion.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment
Outcome: 2 Need for blood transfusion
Study or subgroup
Ligation
plus
vasopressin No treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zhao 2011 0/35 5/35 100.0 % 0.08 [ 0.00, 1.47 ]
Total (95% CI) 35 35 100.0 % 0.08 [ 0.00, 1.47 ]
Total events: 0 (Ligation plus vasopressin), 5 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.089)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
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Analysis 12.3. Comparison 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment,
Outcome 3 Duration of surgery (min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment
Outcome: 3 Duration of surgery (min)
Study or subgroup
Ligation
plus
vasopressin No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zhao 2011 35 71.42 (15.76) 35 104.18 (18.51) 100.0 % -32.76 [ -40.81, -24.71 ]
Total (95% CI) 35 35 100.0 % -32.76 [ -40.81, -24.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.97 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 12.4. Comparison 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment,
Outcome 4 Duration of hospital stay (days).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 12 Loop ligation of myoma pseudocapsule plus vasopressin versus no treatment
Outcome: 4 Duration of hospital stay (days)
Study or subgroup
Ligation
plus
vasopressin No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Zhao 2011 35 3.13 (0.45) 35 4.59 (1.08) 100.0 % -1.46 [ -1.85, -1.07 ]
Total (95% CI) 35 35 100.0 % -1.46 [ -1.85, -1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.38 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.1. Comparison 13 Temporary clipping of uterine artery versus no treatment, Outcome 1 Need
for blood transfusion.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 13 Temporary clipping of uterine artery versus no treatment
Outcome: 1 Need for blood transfusion
Study or subgroup Temporary clipping No treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vercellino 2012 0/80 0/86 Not estimable
Total (95% CI) 80 86 Not estimable
Total events: 0 (Temporary clipping), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours clipping Favours no treatment
Analysis 13.2. Comparison 13 Temporary clipping of uterine artery versus no treatment, Outcome 2
Duration of surgery (min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 13 Temporary clipping of uterine artery versus no treatment
Outcome: 2 Duration of surgery (min)
Study or subgroup Temporary clipping No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vercellino 2012 80 168 (30.4) 86 128 (35.2) 100.0 % 40.00 [ 30.01, 49.99 ]
Total (95% CI) 80 86 100.0 % 40.00 [ 30.01, 49.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.85 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.3. Comparison 13 Temporary clipping of uterine artery versus no treatment, Outcome 3
Postoperative haemoglobin drop (g/dl).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 13 Temporary clipping of uterine artery versus no treatment
Outcome: 3 Postoperative haemoglobin drop (g/dl)
Study or subgroup Temporary clipping No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vercellino 2012 80 1.2 (0.95) 86 1.45 (1.38) 100.0 % -0.25 [ -0.61, 0.11 ]
Total (95% CI) 80 86 100.0 % -0.25 [ -0.61, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 13.4. Comparison 13 Temporary clipping of uterine artery versus no treatment, Outcome 4
Duration of hospital stay (days).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 13 Temporary clipping of uterine artery versus no treatment
Outcome: 4 Duration of hospital stay (days)
Study or subgroup Temporary clipping No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vercellino 2012 80 4.8 (0.1) 86 4.8 (0.7) 100.0 % 0.0 [ -0.15, 0.15 ]
Total (95% CI) 80 86 100.0 % 0.0 [ -0.15, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 13.5. Comparison 13 Temporary clipping of uterine artery versus no treatment, Outcome 5
Postoperative complications.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 13 Temporary clipping of uterine artery versus no treatment
Outcome: 5 Postoperative complications
Study or subgroup Temporary clipping No treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Postoperative bleeding
Vercellino 2012 2/80 1/86 100.0 % 2.18 [ 0.19, 24.51 ]
Subtotal (95% CI) 80 86 100.0 % 2.18 [ 0.19, 24.51 ]
Total events: 2 (Temporary clipping), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 Uterine hematoma
Vercellino 2012 3/80 1/86 100.0 % 3.31 [ 0.34, 32.51 ]
Subtotal (95% CI) 80 86 100.0 % 3.31 [ 0.34, 32.51 ]
Total events: 3 (Temporary clipping), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
3 Postoperative sepsis
Vercellino 2012 1/80 0/86 100.0 % 3.26 [ 0.13, 81.29 ]
Subtotal (95% CI) 80 86 100.0 % 3.26 [ 0.13, 81.29 ]
Total events: 1 (Temporary clipping), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
4 Bleeding from point of trocar insertion
Vercellino 2012 1/80 0/86 100.0 % 3.26 [ 0.13, 81.29 ]
Subtotal (95% CI) 80 86 100.0 % 3.26 [ 0.13, 81.29 ]
Total events: 1 (Temporary clipping), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
5 Postoperative urinary tract infection
Vercellino 2012 1/80 0/86 100.0 % 3.26 [ 0.13, 81.29 ]
Subtotal (95% CI) 80 86 100.0 % 3.26 [ 0.13, 81.29 ]
Total events: 1 (Temporary clipping), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
6 Trocar site hernia
Vercellino 2012 1/80 0/86 100.0 % 3.26 [ 0.13, 81.29 ]
Subtotal (95% CI) 80 86 100.0 % 3.26 [ 0.13, 81.29 ]
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(Continued . . . )
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(. . . Continued)
Study or subgroup Temporary clipping No treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 1 (Temporary clipping), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
7 Sinus venous thrombosis
Vercellino 2012 1/80 0/86 100.0 % 3.26 [ 0.13, 81.29 ]
Subtotal (95% CI) 80 86 100.0 % 3.26 [ 0.13, 81.29 ]
Total events: 1 (Temporary clipping), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
8 Lung artery embolism
Vercellino 2012 0/80 1/86 100.0 % 0.35 [ 0.01, 8.82 ]
Subtotal (95% CI) 80 86 100.0 % 0.35 [ 0.01, 8.82 ]
Total events: 0 (Temporary clipping), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
9 Cardiac arrhythmia
Vercellino 2012 0/80 1/86 100.0 % 0.35 [ 0.01, 8.82 ]
Subtotal (95% CI) 80 86 100.0 % 0.35 [ 0.01, 8.82 ]
Total events: 0 (Temporary clipping), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 2.87, df = 8 (P = 0.94), I2 =0.0%
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Analysis 14.1. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 1 Blood loss (ml).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 14 Fibrin sealant patch versus no treatment
Outcome: 1 Blood loss (ml)
Study or subgroup Tachosil No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Leone Maggiore 2011 35 124.6 (41) 35 151.1 (35.5) 100.0 % -26.50 [ -44.47, -8.53 ]
Total (95% CI) 35 35 100.0 % -26.50 [ -44.47, -8.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.0038)
Test for subgroup differences: Not applicable
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Analysis 14.2. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 2 Postoperative blood
loss in drainage bag.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 14 Fibrin sealant patch versus no treatment
Outcome: 2 Postoperative blood loss in drainage bag
Study or subgroup Tachosil No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Leone Maggiore 2011 35 228 (41.2) 35 272.6 (46) 100.0 % -44.60 [ -65.06, -24.14 ]
Total (95% CI) 35 35 100.0 % -44.60 [ -65.06, -24.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.27 (P = 0.000019)
Test for subgroup differences: Not applicable
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Analysis 14.3. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 3 Need for blood
transfusion.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 14 Fibrin sealant patch versus no treatment
Outcome: 3 Need for blood transfusion
Study or subgroup Tachosil No treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leone Maggiore 2011 0/35 0/35 Not estimable
Total (95% CI) 35 35 Not estimable
Total events: 0 (Tachosil), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 14.4. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 4 Duration of surgery
(min).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 14 Fibrin sealant patch versus no treatment
Outcome: 4 Duration of surgery (min)
Study or subgroup Tachosil No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Leone Maggiore 2011 35 98.4 (7.8) 35 98.8 (9.5) 100.0 % -0.40 [ -4.47, 3.67 ]
Total (95% CI) 35 35 100.0 % -0.40 [ -4.47, 3.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 14.5. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 5 Duration of hospital
stay (days).
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 14 Fibrin sealant patch versus no treatment
Outcome: 5 Duration of hospital stay (days)
Study or subgroup Tachosil No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Leone Maggiore 2011 35 2 (0.19) 35 2 (0.19) 100.0 % 0.0 [ -0.09, 0.09 ]
Total (95% CI) 35 35 100.0 % 0.0 [ -0.09, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 14.6. Comparison 14 Fibrin sealant patch versus no treatment, Outcome 6 Conception after
surgery.
Review: Interventions to reduce haemorrhage during myomectomy for fibroids
Comparison: 14 Fibrin sealant patch versus no treatment
Outcome: 6 Conception after surgery
Study or subgroup Tachosil No treatment Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Leone Maggiore 2011 8/35 3/35 100.0 % 3.16 [ 0.76, 13.11 ]
Total (95% CI) 35 35 100.0 % 3.16 [ 0.76, 13.11 ]
Total events: 8 (Tachosil), 3 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Cochrane Menstrual Disorders and Subfertility Group search strategy for this review
MDSG SS for EJK1071 17.06.14
Search string
Keywords CONTAINS “myomectomy” or Title CONTAINS “myomectomy”
AND
Keywords CONTAINS “misoprostol” or “sulprostone” or “tourniquet” or “uterine artery embolization” or “uterine artery ligation”
or “laser” or “haemorrhages” or “haemostasis” or “haemostatic factors” or “hemostasis” or “uterotonics” or “oxytocin” or “vasopressin”
or “morcellation” or “morcellator” or “bupivacaine” or “Epinephrine” or “blood loss” or “Blood Loss, Surgical” or dinoprostone or
“prostaglandins” or “Bleeding” or Title CONTAINS “misoprostol” or “sulprostone” or “tourniquet” or “uterine artery embolization”
or “uterine artery ligation” or “laser” or “haemorrhages” or “haemostasis” or “haemostatic factors” or “hemostasis” or “uterotonics”
or “oxytocin” or “vasopressin” or “morcellation” or “morcellator” or “bupivacaine” or “Epinephrine” or “blood loss” or “Blood Loss,
Surgical” or dinoprostone or “prostaglandins” or “Bleeding”“
PsycINFO <1801 to February week 03 2011> search strategy
1 exp Gynecological Disorders/ (1252)
2 myoma$.tw. (17)
3 fibroid$.tw. (29)
4 Leiomyoma$.tw. (9)
5 or/1-4 (1290)
6 myomectom$.tw. (5)
7 Laparotom$.tw. (94)
8 laparoscop$.tw. (185)
9 hysteroscop$.tw. (7)
10 or/6-9 (278)
11 Misoprostol.tw. (33)
12 misoprostol.tw. (33)
13 sulprostone.tw. (4)
14 tourniquet.tw. (99)
15 uterine artery ligation$.tw. (6)
16 uterine artery emboli$.tw. (0)
17 UAE.tw. (117)
18 mesna.tw. (4)
19 (laser adj3 dissection).tw. (5)
20 hemorrhag$.tw. (2585)
21 haemorrhag$.tw. (605)
22 uterotonic$.tw. (2)
23 ergometrin$.tw. (21)
24 Ergonovine.tw. (9)
25 oxytocin$.tw. (1434)
26 vasopressin$.tw. (1976)
27 terlipressin$.tw. (0)
28 uterine artery dissection.tw. (0)
29 morcellation.tw. (1)
30 (chemical$ adj3 dissection).tw. (0)
31 h?emosta$.tw. (116)
32 bupivacaine.tw. (149)
33 epinephrine.tw. (1525)
34 or/11-33 (7930)
35 5 and 10 and 34 (0)
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Appendix 2. MEDLINE
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<1946 to Present>
Search Strategy:
--------------------------------------------------------------------------------
1 exp Myoma/ (2048)
2 myoma$.tw. (4499)
3 fibroid$.tw. (4144)
4 exp Leiomyoma/ (16821)
5 leiomyoma$.tw. (10538)
6 or/1-5 (24210)
7 myomectom$.tw. (2224)
8 exp Uterine Myomectomy/ (111)
9 exp Laparotomy/ (15546)
10 laparotom$.tw. (38261)
11 laparoscop$.tw. (82709)
12 exp Laparoscopy/ or exp Hand-Assisted Laparoscopy/ (68805)
13 exp Hysteroscopy/ (3534)
14 hysteroscop$.tw. (4718)
15 or/7-14 (135540)
16 exp Misoprostol/ (3321)
17 misoprostol.tw. (3711)
18 sulprostone.tw. (608)
19 tourniquet.tw. (4107)
20 uterine artery ligation$.tw. (223)
21 uterine artery emboli$.tw. (1113)
22 UAE.tw. (2160)
23 mesna.tw. (1154)
24 (laser adj3 dissection).tw. (275)
25 hemorrhag$.tw. (145643)
26 haemorrhag$.tw. (40098)
27 uterotonic$.tw. (792)
28 ergometrin$.tw. (534)
29 exp Ergonovine/ (1579)
30 Ergonovine.tw. (887)
31 oxytocin$.tw. (17953)
32 exp Oxytocin/ (16608)
33 vasopressin$.tw. (29732)
34 exp Vasopressins/ (33429)
35 terlipressin$.tw. (554)
36 uterine artery dissection.tw. (6)
37 morcellation.tw. (356)
38 (chemical$ adj3 dissection).tw. (104)
39 h?emosta$.tw. (38396)
40 bupivacaine.tw. (10102)
41 epinephrine.tw. (28702)
42 Dinoprostone.tw. (321)
43 exp Dinoprostone/ (25030)
44 or/16-43 (344668)
45 6 and 15 and 44 (665)
46 randomised controlled trial.pt. (376290)
47 controlled clinical trial.pt. (88554)
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48 randomized.ab. (296481)
49 placebo.tw. (159171)
50 clinical trials as topic.sh. (170414)
51 randomly.ab. (214512)
52 trial.ti. (127660)
53 (crossover or cross-over or cross over).tw. (60985)
54 or/46-53 (929704)
55 exp animals/ not humans.sh. (3951934)
56 54 not 55 (856541)
57 45 and 56 (95)
58 (201310$ or 201311$ or 201312$).ed. (235970)
59 2014$.ed. (458535)
60 2014$.dp. (449300)
61 58 or 59 or 60 (1042058)
62 57 and 61 (5)
Appendix 3. EMBASE
Database: Embase <1980 to 2014 Week 24>
Search Strategy:
--------------------------------------------------------------------------------
1 exp UTERUS MYOMA/ (9594)
2 myoma$.tw. (5831)
3 fibroid$.tw. (6109)
4 exp LEIOMYOMA/ (13409)
5 leiomyoma$.tw. (12331)
6 or/1-5 (29054)
7 myomectomy.tw. (3369)
8 exp MYOMECTOMY/ (3469)
9 exp LAPAROTOMY/ (51818)
10 laparotom$.tw. (45529)
11 laparoscop$.tw. (117162)
12 exp LAPAROSCOPY/ (99372)
13 hysteroscop$.tw. (7419)
14 exp HYSTEROSCOPY/ (7632)
15 or/7-14 (203184)
16 misoprostol.tw. (4826)
17 sulprostone.tw. (639)
18 tourniquet.tw. (4505)
19 uterine artery ligation.tw. (332)
20 uterine artery emboli$.tw. (1654)
21 exp uterine artery embolization/ (2021)
22 mesna.tw. (1429)
23 (laser adj3 dissection).tw. (424)
24 hemorrhag$.tw. (171912)
25 haemorrhag$.tw. (48032)
26 uterotonic$.tw. (1009)
27 ergometrin$.tw. (530)
28 oxytocin$.tw. (18561)
29 hormon$ tourniquet$.tw. (1)
30 vasopressin$.tw. (30846)
31 terlipressin$.tw. (809)
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32 uterine artery dissection.tw. (8)
33 morcellation.tw. (713)
34 (chemical$ adj3 dissection).tw. (100)
35 h?emosta$.tw. (50607)
36 bupivacaine.tw. (12861)
37 epinephrine.tw. (31082)
38 exp prostaglandin E2/ (40681)
39 Dinoprostone.tw. (532)
40 or/16-39 (395204)
41 6 and 15 and 40 (1343)
42 Clinical Trial/ (831601)
43 Randomized Controlled Trial/ (343448)
44 exp randomization/ (62313)
45 Single Blind Procedure/ (18367)
46 Double Blind Procedure/ (113645)
47 Crossover Procedure/ (39147)
48 Placebo/ (240637)
49 Randomi?ed controlled trial$.tw. (98971)
50 Rct.tw. (13930)
51 random allocation.tw. (1308)
52 randomly allocated.tw. (20183)
53 allocated randomly.tw. (1921)
54 (allocated adj2 random).tw. (712)
55 Single blind$.tw. (14252)
56 Double blind$.tw. (140404)
57 ((treble or triple) adj blind$).tw. (370)
58 placebo$.tw. (197255)
59 prospective study/ (252453)
60 or/42-59 (1358985)
61 case study/ (26347)
62 case report.tw. (258214)
63 abstract report/ or letter/ (891787)
64 or/61-63 (1170729)
65 60 not 64 (1321392)
66 41 and 65 (240)
67 (201310$ or 201311$ or 201312$).em. (67086)
68 2014$.em. (812650)
69 2014$.dp. (52878)
70 67 or 68 or 69 (881905)
71 66 and 70 (15)
Appendix 4. CINAHL
EJK1071 CINAHL 17.06.14
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# Query Results
S56 S42 AND S54 date limited from 01.01.13 to 17.06.14 6
S55 S42 AND S54 69
S54 S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR
S50 OR S51 OR S52 OR S53
895,110
S53 TX allocat* random* 3,921
S52 (MH ”Quantitative Studies“) 12,109
S51 (MH ”Placebos“) 8,760
S50 TX placebo* 31,698
S49 TX random* allocat* 3,921
S48 (MH ”Random Assignment“) 37,387
S47 TX randomi* control* trial* 73,723
S46 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl*
n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*)
or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1
mask*) )
718,901
S45 TX clinic* n1 trial* 163,832
S44 PT Clinical trial 76,084
S43 (MH ”Clinical Trials+“) 175,691
S42 S6 AND S15 AND S41 291
S41 S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR
S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR
S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR
S37 OR S38 OR S39 OR S40
47,390
S40 TX epinephrine 4,072
S39 TX bupivacaine 2,850
S38 TX haemosta* 726
S37 TX hemosta* 5,008
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(Continued)
S36 TX (chemical* N3 dissection*) 14
S35 ”(chemical$ N3 dissection)“ 0
S34 TX morcellation* 41
S33 TX uterine artery dissection* 0
S32 TX terlipressin* 99
S31 (MH ”Vasopressins“) 1,306
S30 TX vasopressin* 1,650
S29 (MH ”Oxytocin“) OR ”oxytocin“ 1,561
S28 (MM ”Ergonovine“) OR ”Ergonovine“ 96
S27 TX Eergometrin* 0
S26 TX uterotonic* 108
S25 TX haemorrhag* 3,146
S24 TX hemorrhag* 31,367
S23 TX (laser N3 dissection) 14
S22 TX mesna 58
S21 TX UAE 550
S20 TX uterine artery emboli* 442
S19 (MM ”Uterine Artery Embolization“) OR ”uterine artery lig-
ation“
157
S18 (MM ”Tourniquets“) OR ”tourniquet“ 672
S17 ”sulprostone“ 13
S16 (MM ”Misoprostol“) 678
S15 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 25,624
S14 (MH ”Surgery, Gynecologic+“) OR ”gynaecologial surgery“ 8,498
S13 TX Hysteroscop* 803
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(Continued)
S12 (MH ”Hysteroscopy“) 632
S11 (MH ”Laparoscopy“) OR (MM ”Surgery, Laparoscopic“) 10,835
S10 TX laparoscop* 15,437
S9 TX laparotom* 3,348
S8 (MM ”Laparotomy“) 668
S7 TX myomectom* 302
S6 S1 OR S2 OR S3 OR S4 OR S5 2,409
S5 TX fibroid* 832
S4 TX leiomyoma* 2,044
S3 (MM ”Leiomyoma“) OR ”Leiomyoma“ 1,970
S2 TX myoma* 282
S1 (MH ”Myoma+“) OR ”Myoma“ 258
Appendix 5. CENTRAL
Database: EBM Reviews - Cochrane Central Register of Controlled Trials <May 2014>
Search Strategy:
--------------------------------------------------------------------------------
1 exp Myoma/ (16)
2 myoma$.tw. (230)
3 fibroid$.tw. (261)
4 exp Leiomyoma/ (372)
5 leiomyoma$.tw. (209)
6 or/1-5 (649)
7 myomectom$.tw. (221)
8 exp Uterine Myomectomy/ (7)
9 exp Laparotomy/ (558)
10 laparotom$.tw. (1203)
11 laparoscop$.tw. (5936)
12 exp Laparoscopy/ or exp Hand-Assisted Laparoscopy/ (3569)
13 exp Hysteroscopy/ (265)
14 hysteroscop$.tw. (482)
15 or/7-14 (7682)
16 exp Misoprostol/ (1003)
17 misoprostol.tw. (1659)
18 sulprostone.tw. (60)
19 tourniquet.tw. (815)
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20 uterine artery ligation$.tw. (10)
21 uterine artery emboli$.tw. (75)
22 UAE.tw. (250)
23 mesna.tw. (153)
24 (laser adj3 dissection).tw. (18)
25 hemorrhag$.tw. (5607)
26 haemorrhag$.tw. (1950)
27 uterotonic$.tw. (109)
28 ergometrin$.tw. (73)
29 exp Ergonovine/ (106)
30 Ergonovine.tw. (36)
31 oxytocin$.tw. (1709)
32 exp Oxytocin/ (860)
33 vasopressin$.tw. (1169)
34 exp Vasopressins/ (1036)
35 terlipressin$.tw. (156)
36 uterine artery dissection.tw. (0)
37 morcellation.tw. (17)
38 (chemical$ adj3 dissection).tw. (3)
39 h?emosta$.tw. (3106)
40 bupivacaine.tw. (5715)
41 epinephrine.tw. (3448)
42 Dinoprostone.tw. (221)
43 exp Dinoprostone/ (926)
44 or/16-43 (24627)
45 6 and 15 and 44 (64)
46 limit 45 to yr=”2013 -Current“ (4)
F E E D B A C K
Pericervical tourniquet data
Summary
Feedback received from Adam Magos on 29th June 2015:
I believe that the analysis of data regarding the use of tourniquets included in this review is misleading. Two studies are included, of
which I was a co-author of one (Taylor et al 2005):
1. The tourniquet in both studies was not placed only around the cervix as stated in the review. In our study, additional suture
tourniquets were placed around the infundibulo-pelvic ligaments to occlude the ovarian arteries. In the study by Ikechebelu, a single
Foley catheter was used around the cervix and infundiblo-pelvic ligaments, a technique which is very different and unlikely to achieve
total occlusion of the uterine and ovarian vessels as does triple tourniquets (which is why we use sutures).
2. We did not release the tourniquets during the surgery, whereas Ikechebelu did so every 30 minutes. Of course, when a tourniquet is
released, the patient bleeds.
These are two fundamental differences which I fear were not appreciated by the authors of this review. In my view, as the two techniques
are so dissimilar, it is not valid to combine the data and then conclude that ”there was no difference in blood loss between the peri-
cervical tourniquet and no treatment“. I hope you agree and I would be grateful if you would revisit this analysis!
PS The title of the paper by Ikechebelu was misquoted in the review - they used the word ”torniquet“ in the title, not ”tourniquet“.
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Reply
The first author of the review comments as follows: The author (Adam Magos) is right. We were aware of the differences (which we
considered minor) between the two studies and that is included in the description of interventions. Given the email from the authors, I agree
that we should not aggregate the data from the two studies.
The review authors have now unpooled these two studies and reported their findings separately throughout the review.
Contributors
Adam Magos, Consultant Gynaecologist, The Royal Free Hospital, London
Review authors
WH A T ’ S N E W
Last assessed as up-to-date: 17 June 2014.
Date Event Description
23 July 2015 Feedback has been incorporated Data from two studies on peri-cervical tourniquet were unpooled in response to
feedback from one of the trial authors
H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 1, 2007
Date Event Description
5 July 2014 New search has been performed Six additional trials have been included in the cur-
rent update (Kalogiannidis 2011; Leone Maggiore
2011; Zhao 2011; Pourmatroud 2012; Vercellino
2012; Shokeir 2013). Five new interventions have
been added to the review: ascorbic acid, dinopros-
tone, loop ligation of myoma pseudocapsule, tempo-
rary clipping of uterine artery and fibrin sealant patch
(surgical patch coated with fibronogen and thrombin
to stop bleeding of internal organs)
5 July 2014 New citation required and conclusions have changed The conclusions of the review have changed.
18 July 2011 New citation required and conclusions have changed Two additional trials have been included in this up-
date. One of the new trials compared peri-cervi-
cal tourniquet with no treatment (Ikechebelu 2010).
With this new trial, there are now two trials on peri-
cervical tourniquet included in this review. The inclu-
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(Continued)
sion of the new trial to this review has changed the
conclusions; unlike the previous versions of the re-
viewwhere we concluded that there is limited evidence
that peri-cervical tourniquet reduce blood loss during
myomectomy, the conclusion in the current updated
version is that there is no evidence that peri-cervical
tourniquet has an effect on blood loss
The other new trial compared the application of
gelatin-thrombin matrix to the uterine incision with
normal saline (Raga 2009). There is evidence from
this second trial that gelatin thrombin matrix reduced
uterine bleeding.The previous versions of this review
did not include any trial on gelatin thrombin matrix
20 September 2010 Amended Contact details updated.
13 February 2009 New citation required but conclusions have not
changed
Two additional trials have been included in this up-
date: one of the new trials compared intravenous oxy-
tocin with a placebo (Wang 2007) and the other
trial compared intravenous infusionof tranexamic acid
with a placebo (Caglar 2008). In addition to the lim-
ited evidence from the original version of this re-
view that misoprostol, vasopressin, bupivacaine plus
epinephrine, tourniquet, andmesnamay reduce bleed-
ing during myomectomy, we found limited evidence
in this updated version that tranexamic acid may also
reduce bleeding. No major changes were made to the
protocol
14 November 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
EJK conceived the systematic review and conducted the literature search.
EJK and CSW developed the protocol, selected studies for inclusion in the review, extracted the data, performed statistical analysis and
interpreted the data, and wrote the systematic review.
EJK is guarantor of the systematic review.
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D E C L A R A T I O N S O F I N T E R E S T
None known
S O U R C E S O F S U P P O R T
Internal sources
• Stellenbosch University (CSW), South Africa.
Professor CS Wiysonge was employed by the Centre for Evidence-based Health Care, Department of Interdisciplinary Health
Sciences, Stellenbosch University, during the current update of the review.
• Braun School of Public Health, Hebrew University (EJK), Israel.
• University of Yaounde I (EJK), Cameroon.
• Liverpool School of Tropical Medicine (EJK), UK.
External sources
• Effective Care Research Unit, East London (EJK), South Africa.
• Wellcome Trust (CSW), UK.
CS Wiysonge receives funding from the Wellcome Trust, through the Clinical Infectious Diseases Research Initiative, University of
Cape Town, South Africa
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There is no significant difference between this review and the original protocol.
Five new interventions have been added to the review: ascorbic acid, dinoprostone, loop ligation of myoma pseudocapsule, temporary
clipping of uterine artery, and fibrin sealant patch (surgical patch coated with fibronogen and thrombin to stop bleeding of internal
organs).
A proposed subgroup analysis on the basis of ethnic background has been deleted.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Blood Loss, Surgical [∗prevention & control]; Blood Transfusion [utilization]; Hemostasis, Surgical [∗methods]; Hemostatics
[∗therapeutic use]; Leiomyoma [∗surgery]; Randomized Controlled Trials as Topic; Tourniquets; Uterine Neoplasms [∗surgery]
MeSH check words
Female; Humans
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